var title_f36_4_36928="T3 nuclear receptor";
var content_f36_4_36928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Schematic representation of the structure of the T3 (triiodothyronine) nuclear receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The region labeled DNA binding is the portion of the receptor that binds to DNA, and the region labeled Ligand binding is the region that binds T3. NH2 denotes the amino-terminal end of the receptor and COOH the carboxy-terminal end.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Utiger RD. The thyroid: Physiology thyrotoxicosis, hypothyroidism, and the painful thyroid. In: Endocrinology and Metabolism, 3rd ed, Felig R, Baxter JD, Frohman LA (Eds), McGraw-Hill, NY 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36928=[""].join("\n");
var outline_f36_4_36928=null;
var title_f36_4_36929="Trapezius muscle palpation";
var content_f36_4_36929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper trapezius muscle palpation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper portion of the trapezius muscle originates from the seven cervical spinous processes and the distal aspect of the acromial process. Palpate the superior trapezius muscle halfway between the acromion and spinous processes. Local muscular tenderness can result from trauma, but the majority of cases are due to reactive cervical muscular strain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36929=[""].join("\n");
var outline_f36_4_36929=null;
var title_f36_4_36930="Patient information: Absent or irregular periods (The Basics)";
var content_f36_4_36930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15427\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/5/19538\">",
"         Patient information: Early menopause (primary ovarian insufficiency) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/16/11523\">",
"         Patient information: Infertility in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/29/28115\">",
"         Patient information: Polycystic ovary syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/61/28626\">",
"         Patient information: Sertoli-Leydig cell tumor (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/12/29891\">",
"         Patient information: Absent or irregular periods (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/46/30437\">",
"         Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Absent or irregular periods (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/absent-or-irregular-periods-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H193937760\">",
"      <span class=\"h1\">",
"       What are absent or irregular periods?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Absent or irregular periods are periods that do not happen at all or that happen less that 6 to 8 times a year. If a woman does not get her period for a while, it might be because she is pregnant. Or in some cases, it might be that she has a medical condition that affects her brain or reproductive system.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193937767\">",
"      <span class=\"h1\">",
"       What causes absent or irregular periods?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Absent or irregular periods can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pregnancy",
"       </li>",
"       <li>",
"        PCOS (which stands for &ldquo;polycystic ovary syndrome&rdquo;). In women with this condition, the ovaries make too much male hormone. This can disrupt a woman&rsquo;s periods and cause excess facial hair, acne, and problems with weight. PCOS is the most common cause of absent or irregular periods.",
"       </li>",
"       <li>",
"        Some medicines, including birth control pills",
"       </li>",
"       <li>",
"        Being too thin or having too little body fat",
"       </li>",
"       <li>",
"        Exercising too much",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Another cause of absent or irregular periods is menopause. Menopause is the time in a woman&rsquo;s life when she naturally stops having periods. Menopause usually occurs between the ages of 45 and 55. But in some women, menopause comes early&mdash;before the age of 40. Early menopause happens when the ovaries run out of eggs earlier than normal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193937774\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You are older than 15 and still have not had your period",
"       </li>",
"       <li>",
"        You used to get periods, but you have not had a period for more than 3 months",
"       </li>",
"       <li>",
"        Your periods happen more than 45 days apart",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193937781\">",
"      <span class=\"h1\">",
"       What other symptoms should I watch for?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Make sure to tell your doctor if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Think you might be pregnant",
"       </li>",
"       <li>",
"        Have family members with irregular periods",
"       </li>",
"       <li>",
"        Have bad acne or hair on your chest or face",
"       </li>",
"       <li>",
"        Have gained weight and are having trouble losing it",
"       </li>",
"       <li>",
"        Have hot flashes, which feel like a wave of heat that starts in your chest and face and then moves through your body",
"       </li>",
"       <li>",
"        Have night sweats, which are hot flashes that happen when you are asleep",
"       </li>",
"       <li>",
"        Have new headaches or trouble seeing",
"       </li>",
"       <li>",
"        Notice milky fluid coming out of your breasts",
"       </li>",
"       <li>",
"        Are under lots of stress",
"       </li>",
"       <li>",
"        Have recently lost weight",
"       </li>",
"       <li>",
"        Are exercising more than you used to",
"       </li>",
"       <li>",
"        Have changed how much you eat or what kinds of foods you eat",
"       </li>",
"       <li>",
"        Are taking any medicines, herbs, or vitamins",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193937788\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, other symptoms, and individual situation.",
"     </p>",
"     <p>",
"      Here are the most common tests doctors use to find the cause of absent or irregular periods:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Pregnancy test &ndash;",
"        </strong>",
"        Pregnancy is a common cause of missed periods. Your doctor will want to find out if you are pregnant before doing any other tests.",
"       </li>",
"       <li>",
"        <strong>",
"         Blood tests &ndash;",
"        </strong>",
"        These measure hormones that affect the reproductive system.",
"       </li>",
"       <li>",
"        <strong>",
"         MRI &ndash;",
"        </strong>",
"        This test uses a large magnet to make detailed pictures of the brain. It can show if there is a problem in the part of the brain that controls the body&rsquo;s hormones.",
"       </li>",
"       <li>",
"        <strong>",
"         Pelvic ultrasound &ndash;",
"        </strong>",
"        This test uses sound waves to make a picture of your uterus, cervix, and vagina (",
"        <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"         figure 1",
"        </a>",
"        ). The picture can show if there is something wrong with these organs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193937795\">",
"      <span class=\"h1\">",
"       How are absent and irregular periods treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your missed periods, and on whether you want to get pregnant. Possible treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Birth control pills to make periods regular",
"       </li>",
"       <li>",
"        Weight loss if you are overweight",
"       </li>",
"       <li>",
"        Medicines to help you get pregnant if you are having trouble getting pregnant on your own",
"       </li>",
"       <li>",
"        Changing the way you eat and exercise, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Eating more calories",
"       </li>",
"       <li>",
"        Gaining weight if you weigh too little (",
"        <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=see_link\">",
"         calculator 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Easing up on exercise, if you exercise a lot",
"       </li>",
"       <li>",
"        Reducing stress",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Hormones to treat hot flashes (if you are going through early menopause)",
"       </li>",
"       <li>",
"        Surgery to fix problems in the reproductive system",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193937802\">",
"      <span class=\"h1\">",
"       Can absent and irregular periods be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of missing periods by eating well and staying at a healthy weight. Being too thin or too heavy can cause irregular periods.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193937809\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11523?source=see_link\">",
"       Patient information: Infertility in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=see_link\">",
"       Patient information: Polycystic ovary syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/5/19538?source=see_link\">",
"       Patient information: Early menopause (primary ovarian insufficiency) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/61/28626?source=see_link\">",
"       Patient information: Sertoli-Leydig cell tumor (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=see_link\">",
"       Patient information: Absent or irregular periods (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30437?source=see_link\">",
"       Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/4/36930?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15427 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36930=[""].join("\n");
var outline_f36_4_36930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193937760\">",
"      What are absent or irregular periods?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193937767\">",
"      What causes absent or irregular periods?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193937774\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193937781\">",
"      What other symptoms should I watch for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193937788\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193937795\">",
"      How are absent and irregular periods treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193937802\">",
"      Can absent and irregular periods be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193937809\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index for adults (Patient information)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/5/19538?source=related_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11523?source=related_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/61/28626?source=related_link\">",
"      Patient information: Sertoli-Leydig cell tumor (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_4_36931="Velaglucerase alfa (glucocerebrosidase): Drug information";
var content_f36_4_36931=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Velaglucerase alfa (glucocerebrosidase): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/15/20724?source=see_link\">",
"    see \"Velaglucerase alfa (glucocerebrosidase): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/22/8547?source=see_link\">",
"    see \"Velaglucerase alfa (glucocerebrosidase): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9942752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      VPRIV&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11575112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      VPRIV&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9961596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9961744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Gaucher&rsquo;s disease (type 1):",
"     </b>",
"     I.V.: 60 units/kg administered every other week; adjust based upon disease activity (range: 15-60 units/kg evaluated in clinical trials)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     When switching from imiglucerase to velaglucerase alfa in stable patients, initiate treatment at the same dose.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9961703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/22/8547?source=see_link\">",
"      see \"Velaglucerase alfa (glucocerebrosidase): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Gaucher&rsquo;s disease (type 1):",
"     </b>",
"     Children &ge;4 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9961745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9961750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VPRIV&trade;: 400 units [contains sucrose 200 mg/vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9961594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9961746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 1 hour; use an inline, low protein-binding 0.2 micron filter during infusion. Do not infuse other products in the same infusion tubing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9961599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term enzyme replacement therapy for patients with type 1 Gaucher&rsquo;s disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9961687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (30% to 35%), fatigue (13%), fever (13% to 22%; more common in children), dizziness (8% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (15% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: aPPT prolonged (5% to 11%; more common in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infections (30% to 32%; more common in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infusion-related reactions (23% to 52%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular:  Flushing (&gt;2%), hyper-/hypotension (&gt;2%), tachycardia (&gt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash ( &gt;2%; more common in children), urticaria (&gt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9961603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9961684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: The development of IgG antibodies has been reported; the clinical significance is unknown. Patients with an immune response to other enzyme replacement therapies who are switching to velaglucerase alfa should be monitored for antibody development.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Use with caution in patients who have exhibited hypersensitivity reactions to velaglucerase alfa or other enzyme replacement therapies. Appropriate medical support should be readily available in the event of a serious reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infusion-related reaction: Infusion-related reactions (eg, dizziness, fatigue, fever, headache, hyper-/hypotension, nausea) were the most commonly reported adverse drug reactions in clinical trials. Most reactions were mild and occurred during the first 6 months of treatment. Management strategies of more severe reactions include symptomatic treatment, pretreatment with antihistamines, antipyretics, and/or corticosteroids, and slowing of the infusion rate.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10073433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9961600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9961601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies when administered at ~2-4 times the human dose based on body surface area. There are no adequate and well-controlled studies in pregnant women. Use only if clearly indicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9961602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Vpriv Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit (1): $1620.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9961748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disease monitoring: CBC, liver enzymes, IgG antibodies; MRI, CT, or US of liver and spleen; bone density studies; monitor antibodies in those patients who developed antibodies to other enzyme replacement therapies",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Vpriv (AU, CH, CZ, DK, EE, FR, IE, IL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9961693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Velaglucerase alfa, an analogue of endogenous glucocerebrosidase, contains the native human enzyme sequence. In patients with type 1 Gaucher&rsquo;s disease, glucocerebrosidase deficiency results in accumulation of glucocerebroside in macrophages, thereby causing the associated signs and symptoms. Velaglucerase alfa is used to diminish hepatosplenomegaly and improve anemia, thrombocytopenia, and bone disease.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9961695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Steady-state: 0.08-.0.11 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 11-12 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baldellou A, Andria G, Campbell PE, et al, \"Paediatric Non-Neuronopathic Gaucher Disease: Recommendations for Treatment and Monitoring,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2004, 163(2):67-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36931/abstract-text/14677062/pubmed\" id=\"14677062\" target=\"_blank\">",
"        14677062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Charrow J, Andersson HC, Kaplan P, et al, \"Enzyme Replacement Therapy and Monitoring for Children With Type 1 Gaucher Disease: Consensus Recommendations,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2004, 144(1):112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36931/abstract-text/14722528/pubmed\" id=\"14722528\" target=\"_blank\">",
"        14722528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jmoudiak M and Futerman AH, \"Gaucher Disease: Pathological Mechanisms and Modern Management,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2005, 129(2):178-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36931/abstract-text/15813845/pubmed\" id=\"15813845\" target=\"_blank\">",
"        15813845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pastores GM, Weinreb NJ, Aerts H, et al, \"Therapeutic Goals in the Treatment of Gaucher Disease,\"",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 2004, 41(4 Suppl 5):4-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36931/abstract-text/15468045/pubmed\" id=\"15468045\" target=\"_blank\">",
"        15468045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinreb NJ, Aggio MC, Andersson HC, et al, \"Gaucher Disease Type 1: Revised Recommendations on Evaluations and Monitoring for Adult Patients,\"",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 2004, 41(4 Suppl 5):15-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36931/abstract-text/15468046/pubmed\" id=\"15468046\" target=\"_blank\">",
"        15468046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9979 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36931=[""].join("\n");
var outline_f36_4_36931=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9942752\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11575112\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961596\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961744\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961703\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961745\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961750\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961594\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961746\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961599\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961687\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961603\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961684\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300212\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10073433\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961600\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961601\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961602\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322831\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961748\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962020\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961693\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961695\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9979\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9979|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/15/20724?source=related_link\">",
"      Velaglucerase alfa (glucocerebrosidase): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/22/8547?source=related_link\">",
"      Velaglucerase alfa (glucocerebrosidase): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_4_36932="Skin changes face pregnancy PI";
var content_f36_4_36932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F84005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F84005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin changes on the face from pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows an example of skin color changes that can happen with pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36932=[""].join("\n");
var outline_f36_4_36932=null;
var title_f36_4_36933="Tenofovir: Patient drug information";
var content_f36_4_36933=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tenofovir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     see \"Tenofovir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/52/36679?source=see_link\">",
"     see \"Tenofovir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viread&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Viread&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done in patients taking this drug for HIV infection. Hepatitis B may get worse after this drug is stopped. Close watching is needed when the drug is stopped. HIV testing may be given to patients taking this drug for hepatitis B.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hepatitis B infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tenofovir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bone disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an irritated pancreas, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take didanosine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3656499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        4",
"       </sub>",
"       to",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of a soft food (applesauce or yogurt) and swallow without chewing. Chewing the food may make it taste very bad.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3656523",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not mix with any liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696181",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use only the scoop that comes with the powder to measure powder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11878 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36933=[""].join("\n");
var outline_f36_4_36933=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225434\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028467\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028469\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028468\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028473\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028474\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028476\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028471\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028472\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028477\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028478\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=related_link\">",
"      Tenofovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/52/36679?source=related_link\">",
"      Tenofovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_4_36934="Screening for cervical cancer in HIV infected women";
var content_f36_4_36934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for cervical cancer in HIV infected women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36934/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36934/contributors\">",
"     William R Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36934/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36934/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36934/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36934/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/4/36934/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of cervical cytology to screen for cervical cancer often permits diagnosis at the preinvasive stage, when treatment can almost always prevent progression to invasive cancer. For this reason, screening for cervical cancer is important in all women. Screening for cervical cancer is of particular concern to HIV infected women and adolescents since the incidence of cervical intraepithelial neoplasia (CIN), as confirmed by colposcopy, is four to five times higher HIV-positive women and adolescents compared to HIV-negative women and adolescents with high risk sexual behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CIN is common in HIV infected women because [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Both HIV and human papilloma virus (HPV) are sexually transmitted, and",
"     </li>",
"     <li>",
"      HIV infected women are more likely to have persistent HPV infection, and",
"     </li>",
"     <li>",
"      Persistent infection with one or more oncogenic HPV subtypes is a major factor in the pathogenesis of premalignant and malignant cervical disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study has reported that, unfortunately, as many as one-fourth of HIV-infected women do not get an annual pap smear, despite seeing a primary care provider during that time period, underscoring the need for continued emphasis on cervical cancer screening in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific issues regarding screening for cervical cancer in HIV-infected women will be reviewed here. Evaluation and management of women with abnormal screening results and general issues regarding screening for cervical cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18665?source=see_link\">",
"     \"Preinvasive and invasive cervical neoplasia in HIV-infected women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CERVICAL CYTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of cervical cytology assessment alone as a screening tool for",
"    <span class=\"nowrap\">",
"     CIN/cancer",
"    </span>",
"    in women with HIV has been controversial, with some studies reporting a low sensitivity for the detection of cytological abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/10-13\">",
"     10-13",
"    </a>",
"    ], while other studies have been more reassuring about the reliability of this technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/1,14-18\">",
"     1,14-18",
"    </a>",
"    ]. Either conventional Pap smears or liquid-based cervicovaginal preparations may be employed for screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link&amp;anchor=H14#H14\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\", section on 'Choosing conventional smears versus liquid-based cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical cytology appears to be reliable as a primary screening tool for cervical neoplasia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 391 HIV-seropositive and 103 seronegative women with atypical squamous cells (ASC) or low-grade squamous intraepithelial lesions (LSIL) on cervical cytology and negative colposcopy were followed for a mean of four years with cytology at six-month intervals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/21\">",
"       21",
"      </a>",
"      ]. HIV-infected women had a slightly higher risk of progression than HIV-negative women, but the absolute risk was low and did not justify further therapy.",
"     </li>",
"     <li>",
"      In another study, the HIV Epidemiology Research (HER) Study group followed 189 HIV-infected women for six years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/22\">",
"       22",
"      </a>",
"      ]. Agreement between cytologic findings and colposcopic and histologic findings was high, which led them to conclude that the routine use of colposcopy in these individuals was not necessary.",
"     </li>",
"     <li>",
"      A multicenter study conducted in Europe and South Africa attempted to follow 1534 HIV-positive women using cytology, HPV testing, and colposcopy (with histopathology when indicated) at six-month intervals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/17\">",
"       17",
"      </a>",
"      ]. Median follow-up was about two years. Cytology (&ge;ASCUS) and colposcopy had equivalent sensitivity for detecting women with CIN 2 or worse (100 and 98 percent, respectively). HPV testing had similar sensitivity (91 percent), but was much less specific (50 percent versus 65 percent for cytology and 63 percent for colposcopy). Based on these findings, the authors concluded cytology was preferable to HPV testing or colposcopy for screening HIV-positive women for cervical cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines from the American College of Obstetricians and Gynecologists and the United States Preventive Services Task Force recommend that women who are infected with HIV (or otherwise immunocompromised) should undergo cervical cytology for cancer screening twice in the first year after diagnosis of HIV infection and then annually, provided the test results are normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Two cervical screening assessments initially is prudent for HIV infected women since intraepithelial neoplasia is not uncommon and can develop rapidly in these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/2,25\">",
"     2,25",
"    </a>",
"    ] and because high grade lesions may be missed with a single smear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/13\">",
"     13",
"    </a>",
"    ]. The efficacy of annual cervical cytology after consistently negative results was illustrated in a study of 942 HIV-infected women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/26\">",
"     26",
"    </a>",
"    ]. After three consecutive negative cytology results, after 15 months, there were no cases of precancer (CIN 2,3, atypical glandular cells favor neoplasia, or adenocarcinoma in situ), and after 39 months, precancer was found in 2 percent of women. &nbsp;",
"   </p>",
"   <p>",
"    A cost-effectiveness analysis using a simulated clinical practice in the United States also supports this recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/27\">",
"     27",
"    </a>",
"    ]. This report compared six screening strategies in HIV-infected women: no screening; annual Pap smear; annual Pap smear after two negative smears obtained six months apart; semiannual Pap smears; annual colposcopy; and semiannual colposcopy. Annual Pap smear after two negative smears obtained six months apart offered quality adjusted life expectancy benefits at a cost comparable to other clinical preventive interventions. Semiannual Pap smear screening provided additional quality adjusted life years (QALYs) but at significantly greater cost, while colposcopy added significant cost but provided no further benefit.",
"   </p>",
"   <p>",
"    Women with advanced HIV disease (particularly those controlled with highly active antiretroviral therapy) appear to be more likely to have persistent HPV and CIN than those with early HIV infections; however, there are no objective data showing that more aggressive screening is indicated for these women or affects outcome.",
"   </p>",
"   <p>",
"    It has been suggested that the use of highly active antiretroviral therapy (HAART) may reverse or lessen the severity of cervical neoplasia in HIV-infected women, as is the case with other AIDS-related malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. However, multiple studies of this hypothesis have yielded mixed results, and the incidence of invasive cervical neoplasia appears to be unchanged in the HAART era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Follow-up of normal results",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with two consecutive normal cytological examinations, we recommend that annual follow-up include a thorough visual inspection of the anus, vulva, and vagina, as well as the cervix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Evaluation of abnormal results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society for Colposcopy and Cervical Pathology 2006 consensus guidelines advise that immunosuppressed women, including women who are HIV positive, with ASC-US may be managed the same as women in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Women in this population do not appear to be at increased risk of CIN 2,3 or HPV positivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Other cytologic abnormalities in women infected with HIV should also be evaluated in the same manner as in other women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rates of cytologic glandular abnormalities appear to increase with degree of immunosuppression in HIV-positive women, glandular neoplasia is rare. This was illustrated in a large cohort study that included almost 50,000 Pap tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/40\">",
"     40",
"    </a>",
"    ]. Rates of glandular abnormalities on cervical cytology did not differ significantly in HIV-positive (0.8 percent) compared with HIV-negative women (0.6 percent). Among HIV-positive women, on the other hand, the rate cytologic glandular abnormalities increased significantly with decreasing CD4 lymphocyte count",
"    <span class=\"nowrap\">",
"     (&gt;500/mm3:",
"    </span>",
"    0.6 percent; 250 to",
"    <span class=\"nowrap\">",
"     500/mm3:",
"    </span>",
"    0.8 percent;",
"    <span class=\"nowrap\">",
"     &lt;250/mm3:",
"    </span>",
"    1.0 percent). Ultimately, cervical biopsy found only one HIV-positive woman with cervical adenocarcinoma and one HIV-negative woman with glandular atypia; other women had negative histology or squamous abnormalities and showed no significant difference by HIV serostatus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Screening after hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little information about the prevalence of vaginal intraepithelial neoplasia in HIV-infected women who have undergone hysterectomy and how best to follow these women. Uninfected women with no history of CIN who undergo hysterectomy for benign disease have a near zero risk of developing vaginal intraepithelial neoplasia, so periodic vaginal cytological screening is not recommended. Uninfected women with a history of CIN who undergo hysterectomy for CIN or other benign disease have about a 1 percent risk of developing vaginal intraepithelial neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]; therefore, periodic cytology has been advised for these women until three consecutive negative results have been obtained subsequent to the diagnosis of CIN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, a study of 102 HIV-infected women who underwent hysterectomy for a variety of indications reported 16 developed vaginal intraepithelial neoplasia within the first few years after their surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/43\">",
"     43",
"    </a>",
"    ]. Nineteen of these women were known to have CIN I-III or cervical cancer at the time of hysterectomy, seven were known not to have any CIN, and there was no information on the other 76 patients. Of note, the seven women without CIN had normal vaginal cytology during median follow-up of three years. Although the number of patients in this series is small and data are incomplete, the high rate of vaginal intraepithelial neoplasia suggests annual vaginal cytology screening in HIV-infected women is a reasonable approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HUMAN PAPILLOMAVIRUS TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cost-effectiveness study evaluated the role of HPV testing for cervical cancer screening in HIV-infected women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/44\">",
"     44",
"    </a>",
"    ]. For HIV-infected women on antiretroviral therapy, adding HPV testing to the two cervical cytology smears obtained in the first year and then modifying subsequent screening based upon these results (cervical cytology screening every six months for women with detectable HPV DNA and annual screening for all others) was more effective and cost effective than annual screening alone.",
"   </p>",
"   <p>",
"    Others have also found a low risk of cytological abnormalities in immunocompromised women who test negative for high risk subtypes of HPV and have normal CD4 counts. A cohort study showed that HIV-infected women (mean age 37 years) with CD4 counts over",
"    <span class=\"nowrap\">",
"     500/mcL,",
"    </span>",
"    normal cervical cytology, and HPV-negative test results at baseline were at low risk of developing CIN in the next three years, and their risk was equivalent to that of HIV-negative women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, a study of 103 women who were HIV positive and had CD4 counts less than 500 reported the presence of a high risk HPV subtype, although strongly associated with the presence of any CIN, only slightly improved the sensitivity and predictive value of baseline screening when compared to cytologic screening alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/15\">",
"     15",
"    </a>",
"    ]. The lack of substantial benefit was most likely due to the high prevalence of HPV infection in HIV infected women. It appears that HIV infected women are more likely than other women to be infected with high risk HPV subtypes other than 16 and 18 and are likely to have persistent infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We feel the use of HPV testing to determine the frequency of subsequent screening in HIV infected women is a reasonable approach; women who test negative for HPV and have two negative initial cervical cytology results could undergo cytological screening yearly (as discussed above) while those with high risk HPV DNA would have cervical cytology every six months. This is different from the recommendation for HIV-negative women in whom prolongation of the screening interval to not less than three years is recommended if both cytology and HPV results are normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link&amp;anchor=H7#H7\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\", section on 'HPV testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large clinical trials are needed to determine whether subgroups of HIV-positive women, such as those who are HPV negative",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have normal CD4 counts, can be screened for cervical cancer at screening intervals longer than one year. In the meantime, annual screening with more frequent evaluation of those with abnormal cytology or high risk HPV types is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COLPOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians perform routine colposcopy in HIV-infected women, either with the initial cervical cytology or annually. The rationale for this approach is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These women are usually seen in the health care system more often than once a year for other reasons so they would not require an additional visit (with its associated costs and inconvenience) just for screening.",
"     </li>",
"     <li>",
"      The rate of noncompliance is high, thus the potential need for a return visit for colposcopy is eliminated.",
"     </li>",
"     <li>",
"      A higher rate of concurrent vulvar, vaginal, and anal neoplasias occurs in this group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Even mildly abnormal smears are associated with a high rate of histologic CIN (38 percent in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Colposcopic examination of the vagina and vulva, as well as the cervix, should be included in the evaluation because of the higher risk of multifocal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36934/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link\">",
"     \"Colposcopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend a screening colposcopy at initial evaluation. We base the need for subsequent examinations on cervical cytology results (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Evaluation of abnormal results'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who are infected with HIV (or otherwise immunocompromised) should undergo cervical cancer screening twice in the first year after diagnosis of HIV infection and then annually, provided the test results are normal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cervical cytology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with two consecutive normal cytological examinations, we recommend that annual follow-up include a thorough visual inspection of the anus, vulva, and vagina, as well as the cervix. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Follow-up of normal results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no consensus as to whether HPV testing should be performed routinely on HIV infected women. We suggest the use of HPV testing to determine the frequency of subsequent cervical cancer screening in these women; women who test negative for HPV and have two negative initial cervical cytology results could undergo cytological screening yearly while those with high risk HPV DNA should have cervical cytology every six months. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Human papillomavirus testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a screening colposcopy at initial evaluation. The need for subsequent examinations is based upon cervical cytology results. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Colposcopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/1\">",
"      Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/2\">",
"      Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/3\">",
"      Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004; 190:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/4\">",
"      Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/5\">",
"      Clifford GM, Gon&ccedil;alves MA, Franceschi S, HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/6\">",
"      Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/7\">",
"      Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer 2003; 89:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/8\">",
"      Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/9\">",
"      Oster AM, Sullivan PS, Blair JM. Prevalence of cervical cancer screening of HIV-infected women in the United States. J Acquir Immune Defic Syndr 2009; 51:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/10\">",
"      Robinson WR, Barnes SE, Adams S, Perrin MS. Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears. Gynecol Oncol 1997; 65:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/11\">",
"      Olaitan A, Mocroft A, McCarthy K, et al. Cervical abnormality and sexually transmitted disease screening in human immunodeficiency virus-positive women. Obstet Gynecol 1997; 89:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/12\">",
"      Maiman M, Fruchter RG, Sedlis A, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 1998; 68:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/13\">",
"      Robinson WR, Luck MB, Kendall MA, Darragh TM. The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial. Am J Obstet Gynecol 2003; 188:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/14\">",
"      Wright TC Jr, Moscarelli RD, Dole P, et al. Significance of mild cytologic atypia in women infected with human immunodeficiency virus. Obstet Gynecol 1996; 87:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/15\">",
"      Cohn JA, Gagnon S, Spence MR, et al. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. Cervical Disease Study Group of the American Foundation for AIDS Research Community Based Clinical Trials Network. Am J Obstet Gynecol 2001; 184:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/16\">",
"      Boardman LA, Peipert JF, Cooper AS, et al. Cytologic-histologic discrepancy in human immunodeficiency virus-positive women referred to a colposcopy clinic. Obstet Gynecol 1994; 84:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/17\">",
"      Kitchener H, Nelson L, Adams J, et al. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 2007; 121:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/18\">",
"      Boardman LA, Cotter K, Raker C, Cu-Uvin S. Cervical intraepithelial neoplasia grade 2 or worse in human immunodeficiency virus-infected women with mildly abnormal cervical cytology. Obstet Gynecol 2008; 112:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/19\">",
"      Swierczynski SL, Lewis-Chambers S, Anderson JR, et al. Impact of liquid-based gynecologic cytology on an HIV-positive population. Acta Cytol 2004; 48:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/20\">",
"      Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005; 293:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/21\">",
"      Massad LS, Evans CT, Strickler HD, et al. Outcome after negative colposcopy among human immunodeficiency virus-infected women with borderline cytologic abnormalities. Obstet Gynecol 2005; 106:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/22\">",
"      Anderson JR, Paramsothy P, Heilig C, et al. Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis 2006; 42:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/23\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 117: Gynecologic care for women with human immunodeficiency virus. Obstet Gynecol 2010; 116:1492.",
"     </a>",
"    </li>",
"    <li>",
"     United States Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd, Williams and Wilkins, Baltimore  Vol 1996, p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/25\">",
"      Holcomb K, Maiman M, Dimaio T, Gates J. Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus. Obstet Gynecol 1998; 91:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/26\">",
"      Massad LS, D��Souza G, Tian F, et al. Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus. Obstet Gynecol 2012; 120:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/27\">",
"      Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999; 130:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/28\">",
"      Robinson WR, Freeman D. Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy. AIDS Patient Care STDS 2002; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/29\">",
"      Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/30\">",
"      Soncini E, Zoncada A, Condemi V, et al. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed 2007; 78:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/31\">",
"      Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/32\">",
"      Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/33\">",
"      Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/34\">",
"      Palefsky JM. Human papillomavirus-associated anogenital neoplasia and other solid tumors in human immunodeficiency virus-infected individuals. Curr Opin Oncol 1991; 3:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/35\">",
"      Abercrombie PD, Korn AP. Lower genital tract neoplasia in women with HIV infection. Oncology (Williston Park) 1998; 12:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/36\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197:346.",
"     </a>",
"    </li>",
"    <li>",
"     www.ASCCP.org (Accessed on December 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/38\">",
"      Massad LS, Schneider MF, Watts DH, et al. HPV testing for triage of HIV-infected women with papanicolaou smears read as atypical squamous cells of uncertain significance. J Womens Health (Larchmt) 2004; 13:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/39\">",
"      Kirby TO, Allen ME, Alvarez RD, et al. High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus. J Low Genit Tract Dis 2004; 8:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/40\">",
"      Massad LS, Xie X, Darragh TM, et al. Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus. Obstet Gynecol 2009; 114:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/41\">",
"      Gemmell J, Holmes DM, Duncan ID. How frequently need vaginal smears be taken after hysterectomy for cervical intraepithelial neoplasia? Br J Obstet Gynaecol 1990; 97:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/42\">",
"      Wiener JJ, Sweetnam PM, Jones JM. Long term follow up of women after hysterectomy with a history of pre-invasive cancer of the cervix. Br J Obstet Gynaecol 1992; 99:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/43\">",
"      Paramsothy P, Duerr A, Heilig CM, et al. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. J Acquir Immune Defic Syndr 2004; 35:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/44\">",
"      Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 2001; 111:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/45\">",
"      McKenzie ND, Kobetz EN, Hnatyszyn J, et al. Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types. Gynecol Oncol 2010; 116:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36934/abstract/46\">",
"      Heard I, Cubie HA, Mesher D, et al. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG 2013; 120:41.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3220 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36934=[""].join("\n");
var outline_f36_4_36934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CERVICAL CYTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Follow-up of normal results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Evaluation of abnormal results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Screening after hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HUMAN PAPILLOMAVIRUS TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COLPOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18665?source=related_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_4_36935="Clinical manifestations and diagnosis of chronic paracoccidioidomycosis";
var content_f36_4_36935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of chronic paracoccidioidomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36935/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36935/contributors\">",
"     Marcio Nucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36935/contributors\">",
"     Arnaldo L Colombo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36935/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36935/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36935/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/4/36935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracoccidioidomycosis is a systemic endemic mycotic disease caused by the thermally dimorphic fungus, Paracoccidioides brasiliensis. The fungus has a geographic distribution limited to Central and South America, where paracoccidioidomycosis is the most frequent systemic endemic mycosis.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of chronic paracoccidioidomycosis will be reviewed here. The clinical manifestations and diagnosis of",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    paracoccidioidomycosis, as well as the mycology, epidemiology, and treatment of paracoccidioidomycosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40756?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41268?source=see_link\">",
"     \"Mycology and epidemiology of paracoccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30295?source=see_link\">",
"     \"Treatment of paracoccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracoccidioidomycosis occurs predominantly among adult men who work in agriculture and who are between 30 and 60 years of age (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41268?source=see_link&amp;anchor=H3#H3\">",
"     \"Mycology and epidemiology of paracoccidioidomycosis\", section on 'Epidemiology'",
"    </a>",
"    ). As with other systemic endemic fungal infections, any organ can be affected. Following inhalation, Paracoccidioides brasiliensis typically causes asymptomatic pulmonary infection that may be detected by a positive paracoccidioidin intradermal test. If the infection is not contained by the host, the disease may evolve into one of two patterns: the chronic form, which represents reactivation of the primary infection and is most common, and the",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 90 percent of cases of paracoccidioidomycosis are the chronic form, which most commonly affects men who work in agriculture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/2\">",
"     2",
"    </a>",
"    ]. Chronic paracoccidioidomycosis may present months or years following the primary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3\">",
"     3",
"    </a>",
"    ]. Signs and symptoms usually progress slowly, and patients do not typically seek medical attention until several months after the onset of symptoms. Symptoms may be related to a single organ or to several organs. Unifocal disease occurs in only 25 percent of cases, and is most commonly described in the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    P. brasiliensis can disseminate to any part of the body by the hematogenous or lymphatic routes. The chronic form of the disease is usually manifested as pulmonary infiltrates and upper respiratory mucosal lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs are frequently involved in chronic paracoccidioidomycosis, either alone or with other organs. In a review of 352 patients with paracoccidioidomycosis, 77 percent had lung involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3\">",
"     3",
"    </a>",
"    ]. Dry cough and dyspnea are the most frequent presenting symptoms, but sputum production and hemoptysis may occur in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/5\">",
"     5",
"    </a>",
"    ]. However, it is common for patients to present with extensive lung involvement (including fibrosis) with few or no symptoms of pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This is important because there is an increased risk of progressive pulmonary fibrosis among patients with more extensive radiologic findings at the initial presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Sequelae'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Radiographic findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal involvement occurs in over 50 percent of cases. The mouth (oropharynx, lips, tongue, gingiva, palate) is most frequently affected, followed by the larynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The typical lesion is a painful ulcer with ragged borders and small spots of hemorrhage (",
"    <a class=\"graphic graphic_picture graphicRef69875 \" href=\"mobipreview.htm?31/43/32434\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62412 \" href=\"mobipreview.htm?33/43/34483\">",
"     picture 2",
"    </a>",
"    ). Patients complain of soreness, sialorrhea, hoarseness, odynophagia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysphagia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other sites that can be involved in patients with chronic paracoccidioidomycosis include the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/12\">",
"     12",
"    </a>",
"    ], lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/13\">",
"     13",
"    </a>",
"    ], adrenal glands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/14\">",
"     14",
"    </a>",
"    ], and central nervous system (",
"    <a class=\"graphic graphic_picture graphicRef62412 \" href=\"mobipreview.htm?33/43/34483\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/15\">",
"     15",
"    </a>",
"    ]. Adrenal lesions are very common in patients with disseminated disease; this involvement is manifested by asymptomatic limited adrenal reserve in 15 to 40 percent, and less commonly by Addison's disease in approximately 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Less frequently involved organs include bones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/17\">",
"     17",
"    </a>",
"    ], genital organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/19\">",
"     19",
"    </a>",
"    ] and eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung imaging (chest radiograph or CT) typically reveals mixed interstitial and alveolar infiltrates, which are usually perihilar, bilateral, and symmetrical with predominantly lower lung field involvement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63969 \" href=\"mobipreview.htm?34/3/34870\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3,5,7,22\">",
"     3,5,7,22",
"    </a>",
"    ]. Multiple cavitary lesions are a frequent finding. Long-standing pulmonary involvement may lead to serious sequelae such as fibrosis, bullae, and emphysema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74974 \" href=\"mobipreview.htm?30/59/31665\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central nervous system radiographic findings typically include ring enhancing lesions located in the cerebrum, thalamus, cerebellum, brainstem,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spinal cord (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63969 \" href=\"mobipreview.htm?34/3/34870\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joint involvement is characterized by effusion, periarticular bony erosions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    narrowing of the joint space, whereas the typical radiographic finding of bone involvement is bone lysis with or without a rim of sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other radiographic findings depend upon which organs are affected. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Signs and symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important aspect of chronic paracoccidioidomycosis is the development of sequelae, mostly represented by chronic respiratory failure which results from fibrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74974 \" href=\"mobipreview.htm?30/59/31665\">",
"     image 2",
"    </a>",
"    ), and limited adrenal reserve or Addison's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Other sites'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to fibrosis, other pulmonary sequelae include formation of bullae, emphysema, and pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Other sequelae include microstomia and stenosis of the glottis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    trachea with associated dysphonia (",
"    <a class=\"graphic graphic_picture graphicRef57011 \" href=\"mobipreview.htm?34/49/35602\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Importantly, lung scarring occurs even in the setting of adequate antifungal therapy. In a retrospective study of 47 patients with chronic paracoccidioidomycosis who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and were followed for a median of 5.6 years, fibrosis correlated with the severity of the infiltrates at the time of diagnosis. Fibrosis was detected during the study in 83 percent of those with very severe infiltrates at diagnosis compared with 13 percent of patients with mild infiltrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, early diagnosis is of critical importance to prevent progression to fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic paracoccidioidomycosis with lung involvement, there is a broad differential diagnosis, which includes infectious causes such as tuberculosis, fungal infections (especially histoplasmosis), and noninfectious causes such as carcinoma, sarcoidosis, and idiopathic pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. Upper respiratory tract involvement may be suggestive of carcinoma. Mucosal and skin findings may be similar to those of leishmaniasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of paracoccidioidomycosis is based upon the microscopic visualization of fungal elements suggestive of P. brasiliensis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by culturing this fungus from clinical specimens. Serologic testing can be useful both for diagnosis and for monitoring the response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The yeast form of P. brasiliensis can be visualized in sputum, abscess fluid, lymph node aspirates, scrapings of skin lesions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy samples of affected organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/2\">",
"     2",
"    </a>",
"    ]. Routine methods for wet mount preparation include potassium hydroxide (KOH) and calcofluor. Direct microscopy using KOH yields a diagnosis in over 90 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/2\">",
"     2",
"    </a>",
"    ]. A positive direct exam in the proper host is highly suggestive of the diagnosis, even if culture is negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41268?source=see_link&amp;anchor=H2#H2\">",
"     \"Mycology and epidemiology of paracoccidioidomycosis\", section on 'Mycology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When demonstrated in clinical samples, P. brasiliensis is characterized as a large (4 to 40 microns) round or oval \"mother\" yeast cell surrounded by multiple, attached, narrow-necked budding daughter yeast cells (resembling a \"pilot's wheel\") or mother yeast cell possessing only two attached daughter buds (resembling a \"Mickey mouse head\") (",
"    <a class=\"graphic graphic_picture graphicRef74383 \" href=\"mobipreview.htm?8/50/8994\">",
"     picture 4",
"    </a>",
"    ). If the typical multiple budding cells are not found, differentiation from other fungi, such as Blastomyces dermatitidis, can be difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. brasiliensis can be cultured from sputum, biopsy samples,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abscess fluid using Sabouraud dextrose agar or yeast extract agar containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    and cycloheximide incubated at room temperature. The mold form of P. brasiliensis usually takes as long as 20 to 30 days to grow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3\">",
"     3",
"    </a>",
"    ]. Some authors have suggested that cultures for P. brasiliensis are positive in up to 80 percent of samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/2\">",
"     2",
"    </a>",
"    ]. However, in our experience, cultures are frequently negative for P. brasiliensis because most specimens are obtained from sites that are colonized by bacteria which inhibit fungal growth in culture. Consequently, the final diagnosis relies on the identification of typical yeasts cells in direct exam or tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methenamine silver stain or periodic acid Schiff stain are used to identify fungal elements in tissue samples. The presence of the characteristic large round yeast cells with multiple narrow-necked budding yeasts establishes the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef74383 \" href=\"mobipreview.htm?8/50/8994\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Microscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Histopathologic findings include a cellular infiltrate comprised of polymorphonuclear leukocytes, monocytes, macrophages, and multinucleated giant cells, which surround the yeast cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Granulomas surrounding the yeast cells are typical in patients with chronic paracoccidioidomycosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/5\">",
"     5",
"    </a>",
"    ], but may also occur in patients with acute paracoccidioidomycosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of specific antibodies is used for the initial evaluation of patients suspected to be infected by P. brasiliensis, as well as to monitor the response to therapy. Various serologic tests are available, including quantitative immunodiffusion, complement fixation, enzyme-linked immunosorbent assay (ELISA), and counterimmunoelectrophoresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/24\">",
"     24",
"    </a>",
"    ]. The utility of some serologic tests, such as complement fixation and ELISA, is limited by antigenic cross-reactivity between P. brasiliensis and other fungi, especially Histoplasma capsulatum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/2,24\">",
"     2,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quantitative immunodiffusion testing represents the most reliable method for serologic diagnosis, due to its high sensitivity and specificity, and because it is simple to perform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/2\">",
"     2",
"    </a>",
"    ]. It is also the most widely available assay in endemic regions.",
"   </p>",
"   <p>",
"    In a study that used a 7-day exoantigen in the immunodiffusion assay, the sensitivity was 97 percent and the specificity was 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/25\">",
"     25",
"    </a>",
"    ]. Unpublished experience with a larger number of samples suggests lower sensitivity (70 to 90 percent) and specificity (&gt;90 percent). Serologic testing has a lower sensitivity in immunocompromised patients, such as those with HIV infection, than in immunocompetent individuals. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Immunocompromised hosts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For screening of P. brasiliensis infection by serologic testing using immunodiffusion, any positive result should be considered as suggestive of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/1\">",
"     1",
"    </a>",
"    ]. Serologic testing can also be useful for monitoring the response to therapy; a good clinical response is often associated with reduction in the titer of serum antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30295?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of paracoccidioidomycosis\", section on 'Serologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods such as antigen detection may prove particularly useful in immunocompromised patients, in whom serologic testing may be falsely negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/2\">",
"     2",
"    </a>",
"    ]. Detection of the specific glycoprotein antigens, gp43 and gp70, in the serum, cerebrospinal fluid, and bronchoalveolar lavage fluid may be accomplished using immunoenzymatic assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. Preliminary data suggest that this method is probably more sensitive and specific than the traditional antibody detection methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, this test is not commercially available.",
"   </p>",
"   <p>",
"    PCR-based DNA amplification methods have high sensitivity and specificity, but are not widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin testing for the paracoccidioidin antigen is not useful for diagnosis due to its low sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of paracoccidioidomycosis is sought in patients who present with suggestive epidemiological and clinical findings. &nbsp;A typical example would be a man between 30 and 60 years of age who is an agricultural worker in an endemic region and who presents with any of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic lung infiltrates (fibrosis, alveolar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interstitial infiltrates, cavities) with or without symptoms (cough, dyspnea)",
"     </li>",
"     <li>",
"      Chronic mucosal ulcers in the upper airways",
"     </li>",
"     <li>",
"      Sialorrhea, odynophagia, hoarseness",
"     </li>",
"     <li>",
"      Chronic skin lesions (nodules, ulcers) around natural orifices or on the lower limbs",
"     </li>",
"     <li>",
"      Asymmetric lymph node enlargement (especially in the cervical region) with or without fistula formation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of patients with suspected chronic paracoccidioidomycosis should include all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging of affected areas (eg, chest radiograph and CT). Since most patients have chronic pulmonary involvement, multiple lesions, and fibrosis, CT scanning is required to optimally characterize the lung lesions. A baseline chest radiograph is also useful since this modality can be used to follow response to therapy.",
"     </li>",
"     <li>",
"      Direct examination and culture of sputum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy specimens, depending upon sites of involvement",
"     </li>",
"     <li>",
"      Serologic testing (preferably by quantitative immunodiffusion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the diagnosis is often established by direct examination and culture, serologic testing is important in order to have a baseline result for comparison during therapy since a reduction in antibody titers is expected during treatment (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30295?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of paracoccidioidomycosis\", section on 'Serologic testing'",
"    </a>",
"    ). A positive serologic test is also useful in cases in which direct microscopy and culture do not yield a positive result.",
"   </p>",
"   <p>",
"    During the initial evaluation of patients with chronic paracoccidioidomycosis, special attention should be devoted to the lungs (radiographic studies, pulmonary function tests), larynx, oral cavity, adrenal glands, and central nervous system. Abdominal and central nervous system CT scans should be requested only for patients with signs and symptoms suggestive of specific organ involvement.",
"   </p>",
"   <p>",
"    Considering the high frequency of adrenal dysfunction in patients with paracoccidioidomycosis, all patients (regardless of symptoms) should undergo adrenal evaluation at presentation. This includes an early morning serum cortisol level and evaluation of cortisol production in response to exogenous ACTH administration. Patients with clinical suspicion of Addison's disease require a complete investigation of adrenal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Disseminated",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic paracoccidioidomycosis causing disseminated disease is usually made by the detection of characteristic budding yeasts in a tissue biopsy or scrapings of skin or mucosal lesions. Direct examination and cultures of sputum are also useful in detecting fungal elements suggestive of P. brasiliensis. In these patients, the sensitivity of serology is very high and antibody titers by immunodiffusion usually range between 1:8 and 1:64. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Unifocal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis may be challenging in situations in which the disease is restricted to a single organ, especially if the infection is in the central nervous system. In such cases, sensitivity of serology is low, tissue is difficult to obtain, and cultures are frequently negative. The detection of specific antigens (gp48 and gp70) either in the blood or cerebrospinal fluid using an immunoenzymatic assay may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Other methods'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     IMMUNOCOMPROMISED HOSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracoccidioidomycosis has been reported infrequently among patients with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/30-32\">",
"     30-32",
"    </a>",
"    ] or other causes of T-cell mediated immunodeficiency, such as cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/33\">",
"     33",
"    </a>",
"    ] and solid organ transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-infected individuals with paracoccidioidomycosis usually have disseminated disease characterized by more exuberant and widespread findings than those observed in immunocompetent patients with the chronic form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3,30,32\">",
"     3,30,32",
"    </a>",
"    ]. In a retrospective study that included 53 patients with HIV and 106 patients without HIV, HIV-infected patients had more rapid progression of disease and were significantly more likely to have fever (96 versus 51 percent), lymphadenopathy (80 versus 62 percent), hepatomegaly (64 versus 20 percent), and skin lesions (67 versus 46 percent), but were less likely to have ulceration of the oral or nasal mucosa (21 versus 51 percent) compared with non-HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eighty-five percent of HIV-infected individuals had pulmonary involvement compared with 69 percent of non-HIV-infected individuals, a difference which did not reach statistical significance. HIV-infected patients were significantly less likely to have a positive serologic test (76 versus 96 percent). HIV-infected individuals were significantly more likely to have suffered relapse by 24 months (19 versus 3 percent). The majority of HIV-infected patients (84 percent) had a CD4 cell count &le;200",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    This study suggests that paracoccidioidomycosis in HIV-infected patients has different clinical characteristics than the chronic form typically seen in immunocompetent adults. It is surprising that paracoccidioidomycosis does not occur more frequently in HIV-infected patients who live in endemic regions; in such patients, histoplasmosis and cryptococcosis occur more commonly than paracoccidioidomycosis despite a higher incidence of the latter disease in immunocompetent individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36935/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paracoccidioidomycosis is a systemic endemic mycotic disease caused by the thermally dimorphic fungus, Paracoccidioides brasiliensis, which has a geographic distribution limited to Central and South America. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      P. brasiliensis typically causes asymptomatic pulmonary infection. However, if the infection is not contained by the host, the disease may evolve into one of two patterns: the chronic form, which represents reactivation of the primary infection, and the",
"      <span class=\"nowrap\">",
"       acute/subacute",
"      </span>",
"      form. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Over 90 percent of cases of paracoccidioidomycosis occur as the chronic form, which most commonly affects men who work in agriculture. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lungs and oral mucosa are the most frequently involved sites in chronic paracoccidioidomycosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important aspect of chronic paracoccidioidomycosis is the development of sequelae, mostly represented by chronic respiratory failure, which results from fibrosis. Lung scarring occurs even in the setting of adequate antifungal therapy. Adrenal dysfunction is also frequently reported and mostly represented by asymptomatic limited reserve of adrenal function. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sequelae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with chronic paracoccidioidomycosis with lung involvement, there is a broad differential diagnosis, which includes infectious causes such as tuberculosis, fungal infections (especially histoplasmosis), and noninfectious causes such as carcinoma, sarcoidosis, and idiopathic pulmonary fibrosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of paracoccidioidomycosis is based upon the microscopic visualization of fungal elements suggestive of P. brasiliensis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by culturing this fungus from clinical specimens. Serologic testing (preferably quantitative immunodiffusion) can be useful for both diagnosis and monitoring the response to therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic paracoccidioidomycosis should be suspected in patients with chronic lung infiltrates (fibrosis, alveolar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interstitial infiltrates, cavities) with or without symptoms (cough, dyspnea); chronic mucosal ulcers in the upper airways; sialorrhea, odynophagia, or hoarseness; chronic skin lesions (nodules, ulcers);",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      asymmetric lymph node enlargement (especially in the cervical region). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of patients with suspected paracoccidioidomycosis should include imaging of affected areas (eg, chest computed tomography scan), direct examination and culture of sputum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy specimens, and serologic testing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paracoccidioidomycosis has been reported infrequently among patients with HIV or other causes of T-cell mediated immunodeficiency, such as cancer and solid organ transplantation. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Immunocompromised hosts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected individuals with paracoccidioidomycosis usually have disseminated disease characterized by more exuberant and widespread findings than those observed in immunocompetent patients with the chronic form. &nbsp;(See",
"      <a class=\"local\" href=\"#H20\">",
"       'Immunocompromised hosts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/1\">",
"      Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     Restrepo A, Tobon AM, Agudelo CA. Paracoccidioidomycosis. In: Diagnosis and Treatment of Human Mycoses, 1st edition, Hospenthal, DR, Rinaldi, MG (Eds), Humana Press, Totowa, NJ 2008. p.331.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/3\">",
"      Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993; 6:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/4\">",
"      Restrepo A, Benard G, de Castro CC, et al. Pulmonary paracoccidioidomycosis. Semin Respir Crit Care Med 2008; 29:182.",
"     </a>",
"    </li>",
"    <li>",
"     Restrepo, A, Tobon, AM. Paracoccidioides brasiliensis. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell, GL, Bennett, JE, Dolin, R (Eds), Elsevier, Philadelphia 2005, p. 3062.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/6\">",
"      Correa, AL, Franco, L, Restrepo, A. Paracoccidioidomicosis: Coexistencia de lesiones pulmonares y patologia pulmonar silente. Acta Med Colomb 1991; 16:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/7\">",
"      Tob&oacute;n AM, Agudelo CA, Osorio ML, et al. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. Clin Infect Dis 2003; 37:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/8\">",
"      Bicalho RN, Santo MF, de Aguiar MC, Santos VR. Oral paracoccidioidomycosis: a retrospective study of 62 Brazilian patients. Oral Dis 2001; 7:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/9\">",
"      Silva CO, Almeida AS, Pereira AA, et al. Gingival involvement in oral paracoccidioidomycosis. J Periodontol 2007; 78:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/10\">",
"      Godoy H, Reichart PA. Oral manifestations of paracoccidioidomycosis. Report of 21 cases from Argentina. Mycoses 2003; 46:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/11\">",
"      Sant'Anna GD, Mauri M, Arrarte JL, Camargo H Jr. Laryngeal manifestations of paracoccidioidomycosis (South American blastomycosis). Arch Otolaryngol Head Neck Surg 1999; 125:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/12\">",
"      Ramos-E-Silva M, Saraiva Ldo E. Paracoccidioidomycosis. Dermatol Clin 2008; 26:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/13\">",
"      Yamaga LY, Benard G, Hironaka FH, et al. The role of gallium-67 scan in defining the extent of disease in an endemic deep mycosis, paracoccidioidomycosis: a predominantly multifocal disease. Eur J Nucl Med Mol Imaging 2003; 30:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/14\">",
"      Colombo AL, Fai&ccedil;al S, Kater CE. Systematic evaluation of the adrenocortical function in patients with paracoccidioidomycosis. Mycopathologia 1994; 127:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/15\">",
"      Paniago AM, de Oliveira PA, Aguiar ES, et al. Neuroparacoccidioidomycosis: analysis of 13 cases observed in an endemic area in Brazil. Trans R Soc Trop Med Hyg 2007; 101:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/16\">",
"      O&ntilde;ate JM, Tob&oacute;n AM, Restrepo A. [Adrenal gland insufficiency secondary to paracoccidioidomycosis]. Biomedica 2002; 22:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/17\">",
"      Amstalden EM, Xavier R, Kattapuram SV, et al. Paracoccidioidomycosis of bones and joints. A clinical, radiologic, and pathologic study of 9 cases. Medicine (Baltimore) 1996; 75:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/18\">",
"      Doria AS, Taylor GA. Bony involvement in paracoccidioidomycosis. Pediatr Radiol 1997; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/19\">",
"      Severo LC, Kauer CL, Oliveira Fd, et al. Paracoccidioidomycosis of the male genital tract. Report of eleven cases and a review of Brazilian literature. Rev Inst Med Trop Sao Paulo 2000; 42:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/20\">",
"      Cruz AA, Zenha F, Silva JT Jr, Martinez R. Eyelid involvement in paracoccidioidomycosis. Ophthal Plast Reconstr Surg 2004; 20:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/21\">",
"      Dantas AM, Yamane R, Camara AG. South American blastomycosis: ophthalmic and oculomotor nerve lesions. Am J Trop Med Hyg 1990; 43:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/22\">",
"      do Valle AC, Guimar&atilde;es RR, Lopes DJ, Capone D. [Thoracic radiologic aspects in paracoccidioidomycosis]. Rev Inst Med Trop Sao Paulo 1992; 34:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/23\">",
"      Blotta MH, Mamoni RL, Oliveira SJ, et al. Endemic regions of paracoccidioidomycosis in Brazil: a clinical and epidemiologic study of 584 cases in the southeast region. Am J Trop Med Hyg 1999; 61:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/24\">",
"      de Camargo ZP. Serology of paracoccidioidomycosis. Mycopathologia 2008; 165:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/25\">",
"      De Camargo Z, Unterkircher C, Campoy SP, Travassos LR. Production of Paracoccidioides brasiliensis exoantigens for immunodiffusion tests. J Clin Microbiol 1988; 26:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/26\">",
"      Marques da Silva SH, Colombo AL, Blotta MH, et al. Detection of circulating gp43 antigen in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid of patients with paracoccidioidomycosis. J Clin Microbiol 2003; 41:3675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/27\">",
"      Marques da Silva SH, Queiroz-Telles F, Colombo AL, et al. Monitoring gp43 antigenemia in Paracoccidioidomycosis patients during therapy. J Clin Microbiol 2004; 42:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/28\">",
"      Motoyama AB, Venancio EJ, Brand&atilde;o GO, et al. Molecular identification of Paracoccidioides brasiliensis by PCR amplification of ribosomal DNA. J Clin Microbiol 2000; 38:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/29\">",
"      Gomes GM, Cisalpino PS, Taborda CP, de Camargo ZP. PCR for diagnosis of paracoccidioidomycosis. J Clin Microbiol 2000; 38:3478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/30\">",
"      Silva-Vergara ML, Teixeira AC, Curi VG, et al. Paracoccidioidomycosis associated with human immunodeficiency virus infection. Report of 10 cases. Med Mycol 2003; 41:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/31\">",
"      Paniago AM, de Freitas AC, Aguiar ES, et al. Paracoccidioidomycosis in patients with human immunodeficiency virus: review of 12 cases observed in an endemic region in Brazil. J Infect 2005; 51:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/32\">",
"      Morej&oacute;n KM, Machado AA, Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2009; 80:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/33\">",
"      Shikanai-Yasuda MA, Concei&ccedil;&atilde;o YM, Kono A, et al. Neoplasia and paracoccidioidomycosis. Mycopathologia 2008; 165:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/34\">",
"      Zavascki AP, Bienardt JC, Severo LC. Paracoccidioidomycosis in organ transplant recipient: case report. Rev Inst Med Trop Sao Paulo 2004; 46:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36935/abstract/35\">",
"      Shikanai-Yasuda MA, Duarte MI, Nunes DF, et al. Paracoccidioidomycosis in a renal transplant recipient. J Med Vet Mycol 1995; 33:411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2435 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-109.230.63.219-AC07DF7577-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36935=[""].join("\n");
var outline_f36_4_36935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Lungs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mucosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serologic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Disseminated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Unifocal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      IMMUNOCOMPROMISED HOSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2435|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/3/34870\" title=\"diagnostic image 1\">",
"      Paracocci imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/59/31665\" title=\"diagnostic image 2\">",
"      Severe pulmonary paracocci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2435|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/43/32434\" title=\"picture 1\">",
"      Oral paracocci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/43/34483\" title=\"picture 2\">",
"      Chronic paracocci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/49/35602\" title=\"picture 3\">",
"      Paracocci sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/50/8994\" title=\"picture 4\">",
"      Microscopy pilot wheel",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40756?source=related_link\">",
"      Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41268?source=related_link\">",
"      Mycology and epidemiology of paracoccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30295?source=related_link\">",
"      Treatment of paracoccidioidomycosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_4_36936="Group B streptococcal infections in nonpregnant adults";
var content_f36_4_36936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Group B streptococcal infections in nonpregnant adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36936/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36936/contributors\">",
"     Miriam Baron Barshak, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36936/contributors\">",
"     Lawrence C Madoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36936/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36936/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/4/36936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus (GBS; Streptococcus agalactiae) is a gram-positive coccus that frequently colonizes the human genital and gastrointestinal tracts, and the upper respiratory tract in young infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is an important cause of infection in three populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates &mdash; GBS infection is acquired in utero or during passage through the vagina. The most common manifestations of neonatal disease are bacteremia without a focus, sepsis, pneumonia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=see_link\">",
"       \"Group B streptococcal infection in neonates and young infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women &mdash; GBS is a frequent cause of urinary tract infection, chorioamnionitis, postpartum endometritis, and bacteremia in pregnant women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43062?source=see_link\">",
"       \"Group B streptococcal infection in pregnant women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonpregnant adults &mdash; GBS is increasingly recognized as a cause of bacteremia without a focus, sepsis, soft tissue infections, and other focal infections in nonpregnant adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GBS infection in nonpregnant adults will be reviewed here. The microbiology and epidemiology of infections caused by this organism and prevention strategies through chemoprophylaxis and vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9621?source=see_link\">",
"     \"Group B streptococcus: Virulence factors and pathogenic mechanisms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40984?source=see_link\">",
"     \"Vaccines for the prevention of group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite sporadic reports of GBS infection in nonpregnant adults, it was not until intensive population-based surveillance was performed in the 1980s and 1990s that the emergence of this organism as an important pathogen in adults was appreciated.",
"   </p>",
"   <p>",
"    The reported annual incidence of GBS infection in nonpregnant adults in the general population is between 4 and 7 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. However, the risk is as high as 26 per 100,000 in patients &ge;65 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1,5,7\">",
"     1,5,7",
"    </a>",
"    ]. This risk reflects an increase in incidence between 1999 and 2005 in a population-based surveillance study in ten states in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/5\">",
"     5",
"    </a>",
"    ]. In view of the reductions in GBS infection in neonates and pregnant women, GBS infection in adults is now estimated to account for over three-fourths of invasive GBS disease in the United States and for 90 percent of the mortality (",
"    <a class=\"graphic graphic_figure graphicRef87797 \" href=\"mobipreview.htm?21/38/22114\">",
"     figure 1",
"    </a>",
"    ). At least 1300 GBS-related deaths occurred among elderly persons in 2003; the case fatality rate for elderly adults is estimated at 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors for the development of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many groups have attempted to characterize the adult hosts most susceptible to invasive GBS infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1,3,9-16\">",
"     1,3,9-16",
"    </a>",
"    ]. GBS in the gastrointestinal tract is a risk factor for vaginal GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/17\">",
"     17",
"    </a>",
"    ]. In most reports, the infection is equally prevalent in men and women, and some have found a higher rate in African Americans than Caucasians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1,3,4,9\">",
"     1,3,4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes mellitus, malignancy, HIV infection, and advanced hepatic and renal disease have been identified as risk factors for invasive GBS infection in population-based studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1,3,9,14\">",
"     1,3,9,14",
"    </a>",
"    ]. Some studies have also reported higher rates of GBS infection in patients with alcoholism, cardiovascular disease, collagen vascular disease (with or without steroid use), and trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/18\">",
"     18",
"    </a>",
"    ]. The risk is markedly increased in the elderly, particularly nursing home residents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case control study compared patients with invasive GBS infections to patients hospitalized for other illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/14\">",
"     14",
"    </a>",
"    ]. On multivariate analysis, the odds ratios (OR) were highest for the following independent risk factors: cirrhosis (OR 9.7), diabetes mellitus (OR 3.0), stroke (OR 3.5), breast cancer (OR 4.0), decubitus ulcer, (OR 4.0) and neurogenic bladder (OR 4.6). Nosocomial infection, which accounted for 22 percent of these cases, was associated strongly with central venous line placement (OR 30.9), and less strongly with diabetes, congestive heart failure, and seizure disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Carriage of the organism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no obvious immunodeficiency common to patients with the above underlying conditions. Some of these illnesses may simply predispose to bacterial invasion because of a loss of barrier protection in a chronically colonized site. GBS has been isolated from cultures of the human rectum, vagina, cervix, urethra, skin, and pharynx.",
"   </p>",
"   <p>",
"    Women of childbearing age have been most intensively studied for GBS colonization; vaginal and rectal cultures are positive for the organism in 5 to 40 percent of these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/19\">",
"     19",
"    </a>",
"    ]. The carriage rate increases with parity, is inversely correlated with age, and is lower in Mexican-Americans than in African Americans or Caucasians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of colonization in healthy young men and women was evaluated in a report of 462 college students living in a dormitory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/22\">",
"     22",
"    </a>",
"    ]. GBS colonization at one or more site (urine, vagina, anal orifice, throat) was present in 34 percent of the women and 20 percent of the men. The colonization rate was twice as high in sexually experienced compared to inexperienced students, suggesting that GBS may be transmitted by sexual contact.",
"   </p>",
"   <p>",
"    GBS colonization rates have been reported in a number of other groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nursing home residents and staff &mdash; positive rectal cultures for GBS in 12 and 15 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Male homosexuals &mdash; rectal GBS carriage in 25 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A possibly lower carriage rate in diabetics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/25\">",
"       25",
"      </a>",
"      ], even though the incidence of invasive infection is substantially increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1,14\">",
"       1,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serotyping of invasive strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some efforts have been made to identify the strains of GBS involved in infections in nonpregnant adults. GBS are classified into serotypes based upon structural differences in capsular polysaccharides (Ia, Ib, and II-VIII) and the presence or absence of surface protein antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9621?source=see_link\">",
"     \"Group B streptococcus: Virulence factors and pathogenic mechanisms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report comparing the serotype frequency in infants and adults found a predominance of serotype III and serotype Ia, with fewer isolates of serotypes II and V in infant infections. By contrast, the major isolate in adults was serotype V, accounting for 29 percent of the organisms; there were smaller numbers of isolates of serotypes",
"    <span class=\"nowrap\">",
"     Ia/c,",
"    </span>",
"    <span class=\"nowrap\">",
"     Ib/c,",
"    </span>",
"    and III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reports confirm the predominance of serotype V in adult invasive GBS infections and suggest an increasing prevalence of this serotype in perinatal GBS infections as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. Serotypes of GBS colonizing pregnant women have been found to differ in Japanese women, with a high proportion colonized with types VI and VIII, two serotypes rarely found in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/29\">",
"     29",
"    </a>",
"    ]. Emergence of type VIII has been described in Denmark as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/30\">",
"     30",
"    </a>",
"    ]. Serotypes of GBS causing adult infection also probably differ in diverse geographic regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SYNDROMES AND SITES OF CLINICAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A broad spectrum of adult GBS infections has been documented in the literature, both in hospital-based case reports and case series and in population-based surveys. Of these infections, 20 to 70 percent are nosocomial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/11,14\">",
"     11,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Skin and soft tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin and soft tissue infections account for 15 to 40 percent of all bacteremic episodes in population-based surveys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Included in this group are foot and decubitus ulcers, cellulitis, abscesses, necrotizing fasciitis, balanitis, and sternal wound infections after coronary artery bypass grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Several cases of necrotizing fasciitis associated with a toxic shock-like syndrome have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cellulitis is the most frequent clinical manifestation of GBS-associated skin and soft tissue infections. Conditions such as lymphedema, vascular insufficiency, chronic dermatitis, or radiation-induced cutaneous injury are frequent predisposing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/36\">",
"     36",
"    </a>",
"    ]. Post-coital GBS-associated sepsis and thigh cellulitis following sexual intercourse has been described in women with vaginal GBS colonization and predisposing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bacteremia without clear source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary bacteremias comprise 30 to 40 percent of invasive GBS episodes in population-based surveys and are fatal in 20 to 60 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. In some reports most of these infections are nosocomial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. One group found a mean of 16.5 days elapsed between admission and evidence of infection; 81 percent of deaths occurred less than 48 hours after the first blood culture isolate of GBS, despite appropriate treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/12\">",
"     12",
"    </a>",
"    ]. Another study also reported high mortality in inpatients with nosocomial GBS infections but found that most of the deaths were attributable to the underlying disease, which prompted the admission, and to a prolonged hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary tract is the source of 5 to 15 percent of invasive GBS isolates in population-based studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Most of these infections occur in elderly adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/8\">",
"     8",
"    </a>",
"    ]. Genitourinary infections include most commonly cystitis and pyelonephritis, but epididymitis, urethritis, and prostatitis have been reported as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In nonpregnant adults the GBS colony count definition for urinary tract infection is the same as the standard definition of a positive urine culture (&ge;10(5)",
"    <span class=\"nowrap\">",
"     CFU/mL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=see_link\">",
"     \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with urinary tract symptoms, pyuria, and urine culture positive for GBS should receive antimicrobial therapy as outlined below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Upper respiratory tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia accounts for 6 to 12 percent of invasive GBS episodes in population-based reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. However, most of these infections are polymicrobial; GBS is most frequently isolated along with Staphylococcus aureus. A large number of these pneumonias are nosocomial, occur in elderly adults, and have case fatality rates in excess of 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/11,14\">",
"     11,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally GBS is isolated in throat cultures of patients with pharyngitis. In most cases this is likely to be GBS colonization rather than infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bone and joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two to 15 percent of population-based invasive GBS cases involve bone and joint infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. The majority of these infections are osteomyelitis and septic arthritis. Most are community-acquired and develop in large joints, which were already abnormal from prior arthritis, traumatic injury, or joint replacement surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two to 9 percent of invasive GBS isolates infect the heart, usually heart valves, according to population-based studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Endocarditis mainly occurs on native valves, involving the left-sided valves more commonly than the right-sided, and often associated with large, friable vegetations. The typical host in the pre-antibiotic era was a young woman with rheumatic heart disease in the period postpartum or post-abortion. However, the most frequent patient with GBS endocarditis currently is over 50 years old. Young postpartum women constitute a large proportion of patients who develop GBS bacteremia but this group does not commonly develop endocarditis in the absence of pre-existing valvular heart disease.",
"   </p>",
"   <p>",
"    Mortality from GBS endocarditis, whether it presents as an acute or subacute infection, may reach 40 percent, suggesting that GBS valve infections are more virulent than those caused by most other streptococcal species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/40\">",
"     40",
"    </a>",
"    ]. In one study, the mortality rate for prosthetic valve endocarditis was 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/41\">",
"     41",
"    </a>",
"    ]. These mortality rates are similar to those associated with staphylococcal endocarditis. Some groups believe that early surgery should be considered, as there is some suggestion that combined medical-surgical therapy yields better outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/42\">",
"     42",
"    </a>",
"    ]. Pericarditis with GBS has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 4 percent of invasive GBS infections involve the central nervous system (CNS) in population-based surveys; GBS infections account for approximately 1 percent of all cases of meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. GBS meningitis has been described following elective abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/44\">",
"     44",
"    </a>",
"    ]. An increase in adult GBS meningitis has been noted recently in Southeast Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/45\">",
"     45",
"    </a>",
"    ]; reasons for this trend are unclear.",
"   </p>",
"   <p>",
"    GBS infection of the CNS occurs equally among immunocompromised and immunocompetent hosts, with a mortality of approximately 27 percent. Among elderly adults (&ge;65 years) the case fatality rate is as high as 56 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/46\">",
"     46",
"    </a>",
"    ]. The incidence of infection has a bimodal distribution, with peaks in patients in their mid-20s and another in their mid-60s. A large percentage of these patients present with fever, meningismus, neurologic deficits, and spinal fluid glucose, protein, and cell counts suggestive of bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS has been reported as a rare cause of hematogenously seeded endophthalmitis and is associated with poor visual prognosis despite aggressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, the organism has been isolated from peritoneal fluid. The organism is also rarely the etiologic agent in endocarditis and has been recovered from infected pacemakers, abdominal abscesses, mycotic aneurysms, the sinuses, and the biliary tree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/10,14,15,41,48-50\">",
"     10,14,15,41,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Toxic shock-like syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several authors have described patients with a syndrome characterized by fever, rash, hypotension, and electrolyte imbalances in conjunction with urinary tract infections and necrotizing fasciitis caused by GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/33-35,51\">",
"     33-35,51",
"    </a>",
"    ]. In 1993, one group reported the isolation of a \"pyrogenic toxin\" from the supernatant of GBS cultures from these strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/51\">",
"     51",
"    </a>",
"    ]. Rabbits injected subcutaneously with this toxin developed a toxic shock-like picture and died. While these laboratory results were felt to indicate potential toxin production among a subset of GBS strains, no subsequent work has been published in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of GBS from a normally sterile body site (eg, blood, cerebrospinal fluid [CSF], pleural fluid, and bone) confirms the diagnosis of GBS infection. GBS antigen may be detected in CSF, which occasionally may assist in the diagnosis of infection. However, antigen testing of other body fluids is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most GBS infections in adults have no distinctive features that would lead the clinician to suspect that this pathogen would be isolated. Risk factors in the host are usually appreciated after the organism has been recovered in cultures.",
"   </p>",
"   <p>",
"    GBS isolates have traditionally been uniformly penicillin-sensitive, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    is the most active agent in vitro. GBS isolates are also susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , extended-spectrum penicillins and first- and second-generation cephalosporins. For patients who require intravenous treatment, penicillin G (3 to 4 million units IV every four hours) is the treatment of choice. Penicillins and cephalosporins can be administered orally for patients with less severe infections.",
"   </p>",
"   <p>",
"    GBS are believed to be intrinsically resistant to TMP-SMX, and this agent should not be used for treatment. There is significant and rising resistance among GBS isolates to macrolides, tetracyclines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/15\">",
"     15",
"    </a>",
"    ]. Approximately 7 to 55 percent of isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and 3 to 38 percent to clindamycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. An increase in macrolide resistance among isolates of serotype V has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/57\">",
"     57",
"    </a>",
"    ]. Fluoroquinolone resistance has been documented but has been uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]; however, it may be increasing in China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/60\">",
"     60",
"    </a>",
"    ]. GBS isolates with reduced susceptibility to penicillin have been identified in Hong Kong and Japan; these strains remain susceptible to cephalosporins and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who are allergic to penicillins and cephalosporins and require intravenous therapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is an active alternative. For nonpregnant patients with allergy to penicillins and cephalosporins, fluoroquinolones are reasonable empiric oral alternatives. For pregnant patients with allergy to penicillins and cephalosporins, selection of an oral treatment needs to be based on susceptibility of the isolate.",
"   </p>",
"   <p>",
"    The typical duration of therapy is 1 to 3 days for urinary tract infection, 10 days for skin and soft tissue infections, two to three weeks for meningitis, and a minimum of four weeks for osteomyelitis or endocarditis. An aminoglycoside, most often",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , is sometimes added for synergy to treat endocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OUTCOME OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent GBS infection can occur. In one study of 395 nonpregnant adults with GBS infection who survived the initial infection and were followed for at least one year, 17 (4 percent) developed a second infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/13\">",
"     13",
"    </a>",
"    ]. The median age of the patients with recurrent infection was 60 years and all had an underlying disease (systemic lupus erythematosus, cirrhosis, malignancy, diabetes mellitus, renal insufficiency, chronic obstructive pulmonary disease, renal transplant, neurologic disease, and lymphedema). The mean interval between infections was significantly shorter for the 13 patients (72 percent) with the same strain by molecular genetic analysis than for those who had a different strain (14 versus 43 weeks). Relapsed or recurrent infection could have arisen from ongoing gastrointestinal or genitourinary carriage, reinfection from a contact, or an inadequate course of treatment for the initial infection.",
"   </p>",
"   <p>",
"    Overall fatality rate associated with invasive GBS infection in nonpregnant adults varies in different reports. One of the earliest series found only 8 percent mortality, but as many as 25 percent of the cases were postpartum women who generally have better outcomes than other adults with this pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/10\">",
"     10",
"    </a>",
"    ]. Other later studies, which assess adult disease outside of the peripartum period, report mortality rates of 15 to 38 percent, representing up to 90 percent of all GBS-related deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1,3,12,15,26\">",
"     1,3,12,15,26",
"    </a>",
"    ]. Factors associated with worse outcome include: age over 65 years, CNS disease, alcoholism, shock, renal failure, impaired level of consciousness, and confinement to bed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/4,21,62\">",
"     4,21,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts are currently underway to test the efficacy of vaccines composed of purified GBS capsular polysaccharides conjugated to protein carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/63\">",
"     63",
"    </a>",
"    ]. To date, such vaccines have been synthesized and shown to be immunogenic in animal models. In addition, healthy adults have safely received conjugate vaccines prepared with GBS types Ia, Ib, II, III, and V capsular polysaccharides in Phase I and II clinical trials, with results suggesting these conjugate vaccines can effectively prevent invasive GBS disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40984?source=see_link\">",
"     \"Vaccines for the prevention of group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccination is likely to be effective in neonates and in pregnant women, since these groups have been noted to have low titers of antibody directed against GBS capsular polysaccharide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. However, there are some data indicating that adult patients with invasive GBS infection have levels of serum capsular antibody that are high enough to be protective against infection in neonates. One group described 12 patients with invasive GBS infection who had serum collected within 48 hours of the first positive blood culture. Seven of these patients had high levels of IgG against the specific serotype of GBS causing their infection, and these antibodies mediated opsonophagocytic killing of GBS effectively in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/67\">",
"     67",
"    </a>",
"    ]. It is difficult to determine whether the levels of antibody were high at the time of initial infection, or whether they rose rapidly in response to infection.",
"   </p>",
"   <p>",
"    However, these data suggest that antibody deficiency may not be the only reason for susceptibility to infection in adult GBS disease. If this is true, then vaccine development to raise antibody levels may be less than fully effective for preventing invasive GBS disease in adults. Another group has described low levels of serotype V-specific antibody among healthy elderly people, suggesting that the levels may rise during the course of infection and that this population might benefit from vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36936/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Additional study of immune responses in human and animal hosts should allow better understanding of the mechanisms of protective immunity and provide for better prophylaxis and treatment of populations at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H967142\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group B Streptococcus (GBS) is an increasingly recognized cause of bacteremia without a focus, sepsis, soft tissue infections, and other focal infections in nonpregnant adults. Patients with advanced age or underlying chronic diseases including diabetes, cancer, and",
"      <span class=\"nowrap\">",
"       renal/liver",
"      </span>",
"      dysfunction are particularly susceptible, and these infections are associated with high morbidity and mortality despite treatment with appropriate antibiotics. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cellulitis is the most frequent clinical manifestation of GBS-associated skin and soft tissue infections, often in the setting of lymphedema, vascular insufficiency, or chronic dermatitis. Cases of necrotizing fasciitis with a toxic shock-like syndrome have also been reported. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Skin and soft tissue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GBS bacteremia frequently occurs without a clear source. In such cases, the infection is usually nosocomial and is associated with high mortality rates. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bacteremia without clear source'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genitourinary infections include cystitis and pyelonephritis most commonly, in addition to epididymitis, urethritis, and prostatitis. GBS pulmonary infections are typically polymicrobial, most frequently with Staphylococcus aureus. GBS osteomyelitis and septic arthritis are generally community-acquired and affect large joints. Other less common GBS infections include endocarditis, meningitis, endophthalmitis, intraabdominal infections, and mycotic aneurysms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Syndromes and sites of clinical infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GBS can colonize the rectum, vagina, cervix, urethra, skin, and pharynx. Isolation of GBS from a normally sterile body site (eg, blood, cerebrospinal fluid, pleural fluid, and bone) confirms the diagnosis of GBS infection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       Penicillin G",
"      </a>",
"      is the most active agent in vitro, and GBS isolates have traditionally been sensitive to penicillins and cephalosporins. For patients allergic to these agents,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and fluoroquinolones are alternate options. GBS is intrinsically resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , and resistance to macrolides, tetracyclines, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      is rising. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of therapy depends on the type of infection being treated. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High mortality rates have been reported for GBS infections that occur outside the peripartum period. Relapsed and recurrent infections also occasionally occur, possibly from ongoing gastrointestinal or genitourinary carriage, reinfection from a contact, or an inadequate course of treatment for the initial infection. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Outcome of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccines to protect against GBS infection are in the early stages of development, although it is unclear if eliciting anti-GBS antibodies would be an effective strategy to prevent infection in nonpregnant adults. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/1\">",
"      Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/2\">",
"      Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ 1992; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/3\">",
"      Farley MM, Harvey RC, Stull T, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med 1993; 328:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/4\">",
"      Blumberg HM, Stephens DS, Modansky M, et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996; 173:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/5\">",
"      Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/6\">",
"      Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009; 49:85.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, group B streptococcus, 2003. 2004. www.cdc.gov/incidod/dbmd/abcs/survreports/gbs03.pdf (Accessed on September 22, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/8\">",
"      Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis 2005; 41:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/9\">",
"      Schwartz B, Schuchat A, Oxtoby MJ, et al. Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA 1991; 266:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/10\">",
"      Bayer AS, Chow AW, Anthony BF, Guze LB. Serious infections in adults due to group B streptococci. Clinical and serotypic characterization. Am J Med 1976; 61:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/11\">",
"      Verghese A, Mireault K, Arbeit RD. Group B streptococcal bacteremia in men. Rev Infect Dis 1986; 8:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/12\">",
"      Opal SM, Cross A, Palmer M, Almazan R. Group B streptococcal sepsis in adults and infants. Contrasts and comparisons. Arch Intern Med 1988; 148:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/13\">",
"      Harrison LH, Ali A, Dwyer DM, et al. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med 1995; 123:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/14\">",
"      Jackson LA, Hilsdon R, Farley MM, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995; 123:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/15\">",
"      Mu&ntilde;oz P, Llancaqueo A, Rodr&iacute;guez-Cr&eacute;ixems M, et al. Group B streptococcus bacteremia in nonpregnant adults. Arch Intern Med 1997; 157:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/16\">",
"      Henning KJ, Hall EL, Dwyer DM, et al. Invasive group B streptococcal disease in Maryland nursing home residents. J Infect Dis 2001; 183:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/17\">",
"      Meyn LA, Krohn MA, Hillier SL. Rectal colonization by group B Streptococcus as a predictor of vaginal colonization. Am J Obstet Gynecol 2009; 201:76.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/18\">",
"      Perovic O, Crewe-Brown HH, Khoosal M, Karstaedt AS. Invasive group B streptococcal disease in nonpregnant adults. Eur J Clin Microbiol Infect Dis 1999; 18:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/19\">",
"      Dunne DW, Quagliarello V. Group B streptococcal meningitis in adults. Medicine (Baltimore) 1993; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/20\">",
"      Schuchat A, Oxtoby M, Cochi S, et al. Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta. J Infect Dis 1990; 162:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/21\">",
"      Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. Epidemiol Rev 1994; 16:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/22\">",
"      Manning SD, Neighbors K, Tallman PA, et al. Prevalence of group B streptococcus colonization and potential for transmission by casual contact in healthy young men and women. Clin Infect Dis 2004; 39:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/23\">",
"      Kaplan EL, Johnson DR, Kuritsky JN. Rectal colonization by group B beta-hemolytic streptococci in a geriatric population. J Infect Dis 1983; 148:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/24\">",
"      Easmon CS, Tanna A, Munday P, Dawson S. Group B streptococci--gastrointestinal organisms? J Clin Pathol 1981; 34:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/25\">",
"      Casey JI, Maturlo S, Albin J, Edberg SC. Comparison of carriage rates of group B streptococcus in diabetic and nondiabetic persons. Am J Epidemiol 1982; 116:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/26\">",
"      Wessels MR, Kasper DL. The changing spectrum of group B streptococcal disease. N Engl J Med 1993; 328:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/27\">",
"      Harrison LH, Elliott JA, Dwyer DM, et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis 1998; 177:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/28\">",
"      Zaleznik DF, Rench MA, Hillier S, et al. Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis 2000; 30:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/29\">",
"      Lachenauer CS, Kasper DL, Shimada J, et al. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis 1999; 179:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/30\">",
"      Ekelund K, Slotved HC, Nielsen HU, et al. Emergence of invasive serotype VIII group B streptococcal infections in Denmark. J Clin Microbiol 2003; 41:4442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/31\">",
"      Lucks DA, Venezio FR, Lakin CM. Balanitis caused by group B streptococcus. J Urol 1986; 135:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/32\">",
"      Stuesse DC, Robinson JH, Durzinsky DS. A late sternal wound infection caused by hematogenous spread of bacteria. Chest 1995; 108:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/33\">",
"      Gardam MA, Low DE, Saginur R, Miller MA. Group B streptococcal necrotizing fasciitis and streptococcal toxic shock-like syndrome in adults. Arch Intern Med 1998; 158:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/34\">",
"      Holmstr&ouml;m B, Grimsley EW. Necrotizing fasciitis and toxic shock-like syndrome caused by group B streptococcus. South Med J 2000; 93:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/35\">",
"      Tang WM, Ho PL, Yau WP, et al. Report of 2 fatal cases of adult necrotizing fasciitis and toxic shock syndrome caused by Streptococcus agalactiae. Clin Infect Dis 2000; 31:E15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/36\">",
"      Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 2001; 33:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/37\">",
"      Ellison RT 3rd, McGregor JA. Recurrent postcoital lower-extremity streptococcal erythroderma in women. Streptococcal-sex syndrome. JAMA 1987; 257:3260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/38\">",
"      Lefevre JC, Lepargneur JP, Bauriaud R, et al. Clinical and microbiologic features of urethritis in men in Toulouse, France. Sex Transm Dis 1991; 18:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/39\">",
"      Procopiou M, Genn&eacute; D, Abbet P, et al. Acute prostatitis with prostatic abscess caused by group B Streptococcus. Clin Infect Dis 1998; 27:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/40\">",
"      Scully BE, Spriggs D, Neu HC. Streptococcus agalactiae (group B) endocarditis--a description of twelve cases and review of the literature. Infection 1987; 15:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/41\">",
"      Sambola A, Miro JM, Tornos MP, et al. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962-1998. Clin Infect Dis 2002; 34:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/42\">",
"      Roll&aacute;n MJ, San Rom&aacute;n JA, Vilacosta I, et al. Clinical profile of Streptococcus agalactiae native valve endocarditis. Am Heart J 2003; 146:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/43\">",
"      Vartian CV, Septimus EJ. Tricuspid valve group B streptococcal endocarditis following elective abortion. Rev Infect Dis 1991; 13:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/44\">",
"      Deziel PJ, McGuire N, Brown PD. Group B streptococcal meningitis complicating elective abortion: report of 2 cases. Clin Infect Dis 2000; 31:E23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/45\">",
"      Wilder-Smith E, Chow KM, Kay R, et al. Group B streptococcal meningitis in adults: recent increase in Southeast Asia. Aust N Z J Med 2000; 30:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/46\">",
"      Domingo P, Barquet N, Alvarez M, et al. Group B streptococcal meningitis in adults: report of twelve cases and review. Clin Infect Dis 1997; 25:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/47\">",
"      Lee SY, Chee SP. Group B Streptococcus endogenous endophthalmitis : case reports and review of the literature. Ophthalmology 2002; 109:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/48\">",
"      Barnham M. The gut as a source of the haemolytic streptococci causing infection in surgery of the intestinal and biliary tracts. J Infect 1983; 6:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/49\">",
"      Burnet NG, Wilkinson RC, Evans DS. Mycotic aneurysm caused by group B streptococcus: a cautionary tale of management problems and a rare organism. Br J Clin Pract 1990; 44:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/50\">",
"      Baddour LM, Cox JW Jr. Group B streptococcal infection of a pacemaker wire following sigmoidoscopy. Clin Infect Dis 1992; 15:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/51\">",
"      Schlievert PM, Gocke JE, Deringer JR. Group B streptococcal toxic shock-like syndrome: report of a case and purification of an associated pyrogenic toxin. Clin Infect Dis 1993; 17:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/52\">",
"      Fernandez M, Hickman ME, Baker CJ. Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother 1998; 42:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/53\">",
"      Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol 1998; 92:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/54\">",
"      Borchardt SM, DeBusscher JH, Tallman PA, et al. Frequency of antimicrobial resistance among invasive and colonizing Group B streptococcal isolates. BMC Infect Dis 2006; 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/55\">",
"      DiPersio LP, DiPersio JR. High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B Streptococcus. Diagn Microbiol Infect Dis 2006; 54:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/56\">",
"      Back EE, O'Grady EJ, Back JD. High rates of perinatal group B Streptococcus clindamycin and erythromycin resistance in an upstate New York hospital. Antimicrob Agents Chemother 2012; 56:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/57\">",
"      Diekema DJ, Andrews JI, Huynh H, et al. Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J Clin Microbiol 2003; 41:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/58\">",
"      Wehbeh W, Rojas-Diaz R, Li X, et al. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother 2005; 49:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/59\">",
"      Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn Microbiol Infect Dis 2006; 55:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/60\">",
"      Wang H, Zhao C, He W, et al. High prevalence of fluoroquinolone-resistant group B streptococci among clinical isolates in China and predominance of sequence type 19 with serotype III. Antimicrob Agents Chemother 2013; 57:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/61\">",
"      Chu YW, Tse C, Tsang GK, et al. Invasive group B Streptococcus isolates showing reduced susceptibility to penicillin in Hong Kong. J Antimicrob Chemother 2007; 60:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/62\">",
"      Trivalle C, Martin E, Martel P, et al. Group B streptococcal bacteraemia in the elderly. J Med Microbiol 1998; 47:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/63\">",
"      Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996; 98:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/64\">",
"      Paoletti LC, Kasper DL. Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin Biol Ther 2003; 3:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/65\">",
"      Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/66\">",
"      Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics 1981; 68:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/67\">",
"      Wessels MR, Kasper DL, Johnson KD, Harrison LH. Antibody responses in invasive group B streptococcal infection in adults. J Infect Dis 1998; 178:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/68\">",
"      Amaya RA, Baker CJ, Keitel WA, Edwards MS. Healthy elderly people lack neutrophil-mediated functional activity to type V group B Streptococcus. J Am Geriatr Soc 2004; 52:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36936/abstract/69\">",
"      Edwards MS, Rench MA, Palazzi DL, Baker CJ. Group B streptococcal colonization and serotype-specific immunity in healthy elderly persons. Clin Infect Dis 2005; 40:352.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3171 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36936=[""].join("\n");
var outline_f36_4_36936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H967142\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors for the development of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Carriage of the organism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serotyping of invasive strains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SYNDROMES AND SITES OF CLINICAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Skin and soft tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bacteremia without clear source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urinary tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Upper respiratory tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bone and joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Toxic shock-like syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OUTCOME OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H967142\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3171\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3171|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/38/22114\" title=\"figure 1\">",
"      Incidence of GBS in nonpregnant adults by race and age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43062?source=related_link\">",
"      Group B streptococcal infection in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9621?source=related_link\">",
"      Group B streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40984?source=related_link\">",
"      Vaccines for the prevention of group B streptococcal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_4_36937="Efavirenz, tenofovir, and emtricitabine: Pediatric drug information";
var content_f36_4_36937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Efavirenz, tenofovir, and emtricitabine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/25/23961?source=see_link\">",
"    see \"Efavirenz, tenofovir, and emtricitabine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/23/25973?source=see_link\">",
"    see \"Efavirenz, tenofovir, and emtricitabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3053105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atripla&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5505100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atripla&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F5137430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleotide Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F5137461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/25/23961?source=see_link\">",
"      see \"Efavirenz, tenofovir, and emtricitabine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection: Note:",
"     </b>",
"     May be used alone or in combination with other antiretroviral agents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &lt;12 years or &lt;40 kg: Product is a fixed-dose combination; safety and efficacy have not been established; use in patients &lt;40 kg would result in an excessive efavirenz dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years and  Adolescents &ge;40 kg and Adults: Oral: 1 tablet once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Children &ge;12 years, Adolescents, and Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Children &ge;12 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild hepatic impairment (Child-Pugh class A): Use with caution; limited clinical experience.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate to severe hepatic impairment (Child-Pugh class B, C): Not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3053167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atripla&reg;: Efavirenz 600 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9848865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5137462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer dose at bedtime to decrease CNS adverse effects. Administer with water on an empty stomach; administration with food may increase efavirenz concentrations and adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5137438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Keep container tightly closed; do not use if seal on bottle is broken or missing. Dispense only in original container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5137431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection either alone or in combination with other antiretroviral agents (FDA approved in ages &ge;12 years weighing at least 40 kg and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F3053142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The complete adverse reaction profile of combination therapy has not been established.",
"     <b>",
"      See individual agents.",
"     </b>",
"     The following adverse effects were noted in clinical trials with combination therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Abnormal dreams, anxiety, depression, dizziness, fatigue, headache, insomnia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Bone mineral density decreased, hypercholesterolemia, hyperglycemia, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, nausea, serum amylase increased,  vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Creatine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Nasopharyngitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Glycosuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5137433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to efavirenz (including a history of clinically significant  hypersensitivity, such as Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions), emtricitabine, tenofovir, or any component; concurrent therapy with bepridil, cisapride, midazolam, pimozide, triazolam, ergot derivatives, voriconazole, or St John's wort",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6102646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use efavirenz, emtricitabine, and tenofovir with caution in patients with mild hepatic impairment; product is not recommended for patients with moderate or severe hepatic impairment, marked transaminase elevations, known or suspected hepatitis B or C, and in those receiving other hepatotoxic medications; monitor liver enzymes before and during treatment in these patients; weigh risk versus benefit in patients with persistent elevations of serum transaminases (ie, &gt;5 times normal). Hepatic failure (including fatalities and cases requiring liver transplantation) has been reported in patients with no pre-existing liver disease or other known risk factors; consider liver enzyme monitoring in patients without pre-existing liver disease or other known risk factors. Elevations of serum cholesterol and triglycerides may occur; monitor during therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use efavirenz with caution in patients with a history of mental illness or substance abuse (predisposition to psychological reactions); serious psychiatric side effects have been associated with use including aggressive behavior, severe depression, suicidal ideation, suicide, paranoia, and mania; patients should be instructed to contact healthcare provider if serious psychiatric effects occur. Use with caution in patients with a history of seizures; convulsions may occur. Efavirenz may decrease the serum concentrations of antiepileptic agents that are metabolized by the liver; monitor anticonvulsant concentrations periodically. Cross-resistance with other non-nucleoside reverse transcriptase inhibitors may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Emtricitabine-associated hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults. Tenofovir-associated osteomalacia and reduced bone mineral density (BMD) may occur; long-term effects in humans are not known. Postmarketing cases of osteomalacia which may increase risk of bone fractures have also been reported in association with proximal renal tubulopathy. Recent studies suggest that tenofovir-related bone loss may be greater in children who are less mature (eg, Tanner stage 1-2) than in those who are more physically mature (Tanner &ge;3). A significant decrease in lumbar spine BMD (&gt;6%) was reported in five of 15 pediatric patients who received a tenofovir-containing regimen for 48 weeks. No orthopedic fractures occurred, but two patients required discontinuation of tenofovir. All five patients with a decrease in BMD were virologic responders and prepubertal (Tanner Stage 1). This study found a moderately strong correlation between decreases in bone mineral density z scores at week 48 and age at baseline. No correlation between decreases in bone mineral density z scores and tenofovir dose or pharmacokinetics was observed; BMD loss may limit the usefulness of tenofovir in prepubertal children [DHHS (pediatric), 2012; Giacomet, 2005; Hazra, 2005; Purdy, 2008]. Monitor BMD for potential bone toxicities during therapy; supplementation with calcium and vitamin D may be beneficial but has not been studied.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune  reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg. Graves' disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5137434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cases of lactic acidosis, severe hepatomegaly with steatosis, and death have been reported in patients receiving nucleoside analogues (including tenofovir)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue therapy in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity. Testing for hepatitis B is recommended prior to the initiation of efavirenz, emtricitabine, and tenofovir therapy; HIV-infected patients who are coinfected with hepatitis B may experience severe acute exacerbations of hepatitis (ie, clinical symptoms or laboratory evidence of hepatitis) when emtricitabine or tenofovir is discontinued",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; liver decompensation and hepatic failure have been associated with exacerbation of hepatitis B in patients treated with emtricitabine or tenofovir following discontinuation; monitor patients closely (with both clinical and laboratory follow-up) for at least several months after discontinuation of efavirenz, emtricitabine, and tenofovir; initiate antihepatitis B therapy if needed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Efavirenz is a mixed inducer/inhibitor of CYP450 enzymes and numerous drug interactions occur. Due to potential serious and/or life-threatening drug interactions, certain drugs are contraindicated (significant drug interactions may also occur with tenofovir). Emtricitabine and tenofovir are primarily eliminated by the kidney; while efavirenz is not; do not use this fixed dose combination of efavirenz, emtricitabine, and tenofovir in patients with moderate or severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); monitor renal function closely; renal dysfunction, including acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia) has been reported with tenofovir use; this may occur especially in patients with renal disease, underlying systemic disease, or those taking nephrotoxic medications; adults with a low body weight and those taking medications that increase tenofovir serum concentration may also be at increased risk for tenofovir-associated nephrotoxicity; avoid tenofovir in patients with concomitant or recent use of nephrotoxic agents; cases of nephrotoxicity have been reported in adolescents receiving tenofovir-containing regimens; evaluate and monitor renal function in all patients receiving tenofovir (regardless of age).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Efavirenz may cause CNS effects (eg, abnormal dreams, insomnia, impaired concentration, hallucinations, dizziness, or drowsiness). The overall reported incidence of CNS adverse effects was 53% vs 25% in controls; nervous system symptoms in children were reported to be 18%. Fever has been reported with use (children: 21%). CNS symptoms usually begin within 1-2 days after starting efavirenz, and generally resolve within 2-4 weeks of continued therapy. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Tolerability of CNS effects may be improved by dosing at bedtime. CNS effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Efavirenz  may cause a rash, which usually presents as pruritic maculopapular skin eruptions; incidence is more common and more severe in children than in adults [incidence: Adults 26%, children 46%; median onset: Adults: 11 days, children: 9 days (range: 6-205 days)]. Most rashes in children appeared within 14 days after starting therapy [median duration: Adults: 16 days, children: 6 days (range: 2-37 days)]. Median duration of rash in children who continued therapy was 9 days; rash may be treated with antihistamines and corticosteroids and usually resolves within 1 month while continuing therapy. Discontinue if severe rash (involving blistering, desquamation, mucosal involvement, ulceration, or fever) occurs.",
"     <b>",
"      Consider prophylaxis with antihistamines in children due to frequency and severity of rash reported in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Teratogenic effects have been observed in primates receiving efavirenz; human birth defects following efavirenz exposure in the first trimester have been reported, including cases of neural tube defects (including meningomyelocele and Dandy-Walker malformation); women of childbearing potential should be tested for pregnancy before starting efavirenz; women receiving efavirenz should avoid pregnancy while receiving this drug and for 12 weeks after discontinuation of this drug (due to long half-life of efavirenz); barrier contraception in combination with other (hormonal) methods of contraception should be used; avoid use of efavirenz during the first trimester of pregnancy and in women with significant childbearing potential; women who use this drug during the first trimester or who become pregnant while taking this drug should be apprised of the potential harm to the fetus.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Atripla&reg; contains efavirenz, emtricitabine, and tenofovir as a fixed-dose combination; do not administer Atripla&reg; with other efavirenz-, emtricitabine-, or tenofovir-containing medications (eg, Complera&reg;, Emtriva&reg;, Stribild&reg;, Sustiva&reg;, Truvada&reg;, or Viread&reg;) or with medications that contain lamivudine (eg, Epivir&reg;, Epivir-HBV&reg;, Combivir&reg;, Epzicom&reg;, or Trizivir&reg;). Do not coadminister with adefovir; may diminish efficacy of tenofovir. Coadministration with efavirenz may be required for dose adjustment with concomitant rifampin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3053147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3053146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adefovir: May diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir. Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Efavirenz may decrease the serum concentration of Atazanavir.  Management: When used with efavirenz, the atazanavir regimen should be atazanavir 400 mg/ritonavir 100 mg daily for treatment-naive patients; treatment-experienced patients should not use atazanavir together with efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Efavirenz may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Efavirenz may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Efavirenz may enhance the arrhythmogenic effect of Bepridil [Off Market].",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Efavirenz may decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Efavirenz may decrease the serum concentration of BuPROPion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Efavirenz may enhance the QTc-prolonging effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Efavirenz may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks.  Cyclosporine dose adjustment may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Efavirenz may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Efavirenz may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Efavirenz may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Efavirenz may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etonogestrel: Efavirenz may diminish the therapeutic effect of Etonogestrel.  Management: Use a reliable barrier contraceptive if efavirenz is used in combination with etonogestrel.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: Efavirenz may decrease the serum concentration of Everolimus.  Management: Closely monitor everolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of everolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Efavirenz may decrease serum concentrations of the active metabolite(s) of Fosamprenavir.  Management: For once-daily fosamprenavir/ritonavir with efavirenz, an increased ritonavir dose to 300 mg/day is recommended.  No ritonavir dose adjustment is required if using twice-daily fosamprenavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Efavirenz may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Tenofovir may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Efavirenz may decrease the serum concentration of Indinavir.  Management: The appropriate dose adjustments for indinavir when used together with efavirenz are unknown. The use of higher unboosted indinavir doses is not likely an adequate approach.  Use of a ritonavir-boosted indinavir regimen could be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Efavirenz may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Efavirenz may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with efavirenz.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for specific recommended dose increases in particular patient populations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Efavirenz may decrease the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Efavirenz may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Efavirenz may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Efavirenz. Management: Use efavirenz with caution, and monitor for increased adverse effects, during and 2 weeks following discontinuation of mifepristone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Efavirenz may enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norgestimate: Efavirenz may decrease serum concentrations of the active metabolite(s) of Norgestimate.  Management: Use a reliable barrier contraceptive if efavirenz is used in combination with norgestimate.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Efavirenz may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Efavirenz may enhance the arrhythmogenic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Efavirenz may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Efavirenz may decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proguanil: Efavirenz may decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Tenofovir may decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Efavirenz may decrease the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Efavirenz may decrease the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Efavirenz.  Management: If efavirenz is to be used with daily rifabutin, increase the planned rifabutin adult dose by 50%.  If used with regimens where rifabutin is administered 2-3 times per week, consider doubling the rifabutin dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Efavirenz. Management: Increase efavirenz adult dose to 800 mg daily in patients weighing over 50 kg (per U.S. manufacturer; CDC sets this at 60 kg, and Canadian manufacturer recommends the dose increase regardless of weight).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Efavirenz may enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the adverse/toxic effect of Efavirenz. Efavirenz may decrease the serum concentration of Saquinavir. Management: When used together with efavirenz, saquinavir should not be used as the sole protease inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Efavirenz may decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Efavirenz may decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Efavirenz may decrease the serum concentration of Sirolimus.  Management: Closely monitor sirolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of sirolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Efavirenz may decrease the serum concentration of Tacrolimus (Systemic).  Management: Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of tacrolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Efavirenz may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Efavirenz may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Efavirenz may increase the serum concentration of Vitamin K Antagonists. Efavirenz may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole. Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5137437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Effect of food on absorption of Atripla&reg; has not been evaluated. Compared to fasting conditions, high fat/high caloric meals increase efavirenz AUC by 28% and peak concentrations by 79%. Administration of tenofovir and emtricitabine with either a high fat meal or a light meal delayed the time to peak concentrations of tenofovir; mean tenofovir AUC increased by 35% and peak concentrations increased by 15%; emtricitabine AUC and peak concentrations were not affected.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3053111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3053112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5137463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients should be screened for hepatitis B infection before starting therapy. Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine, and creatinine clearance. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphorus, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphorus, lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, rash, CNS and psychiatric effects, bone abnormalities, hyperpigmentation, or lactic acidosis. Monitor weight and growth in children. Consider bone mineral density assessment for all patients with a history of pathologic bone fractures or other risk factors for osteoporosis or bone loss.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5137459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5137460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One Atripla&reg; tablet is bioequivalent to one efavirenz 600 mg tablet plus one emtricitabine 200 mg capsule plus one tenofovir 300 mg tablet (single dose study); see individual agents",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F5137465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/23/25973?source=see_link\">",
"      see \"Efavirenz, tenofovir, and emtricitabine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting efavirenz, emtricitabine, and tenofovir, notify physician about medical conditions, including any liver or kidney problems. Patients with HIV should be tested for hepatitis B before starting therapy. Due to possible teratogenic effects, female patients of childbearing potential should be tested for pregnancy prior to starting efavirenz-containing products and should avoid pregnancy while receiving this drug and for 12 weeks after discontinuation of this drug; barrier contraception with other (hormonal) methods of contraception should be used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Efavirenz, emtricitabine, and tenofovir is not a cure for HIV; take efavirenz, emtricitabine, and tenofovir every day as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose. Some medicines should not be taken with this product; report the use of other medications, nonprescription medications, and herbal or natural products to physician and pharmacist; avoid alcohol and the herbal medicine St John's wort. Inform physician of seizure history or of concurrent use of seizure medications (blood samples to check the level of seizure medications may be needed more frequently when taking efavirenz-containing products).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician immediately if rash develops. Notify physician if persistent severe abdominal pain, nausea, vomiting, rash, numbness, or tingling occur. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Long-term effects are not known. HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Some HIV medications (including emtricitabine and tenofovir) may cause a serious, but rare, condition called lactic acidosis with an increase in liver size (hepatomegaly). Tenofovir may decrease bone mineral density; bone mineral density monitoring may be needed in patients at risk. Atripla&reg; contains efavirenz, emtricitabine, and tenofovir as a fixed-dose combination; do not administer Atripla&reg; with other efavirenz, emtricitabine, or tenofovir-containing medications (eg, Complera&reg;, Emtriva&reg;, Stribild&reg;, Sustiva&reg;, Truvada&reg;, or Viread&reg;) or with medications that contain lamivudine (eg, Epivir&reg;, Epivir-HBV&reg;, Combivir&reg;, Epzicom&reg;, or Trizivir&reg;). Do not take with adefovir (Hepsera&reg;).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36937/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,&rdquo; February 12, 2013. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and  Medical Management of HIV-Infected Children &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giacomet V, Mora S, Martelli L, et al, \"A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children,\"",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 2005, 40(4):448-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36937/abstract-text/16280700/pubmed\" id=\"16280700\" target=\"_blank\">",
"        16280700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hazra R, Gafni RI, Maldarelli F, et al, \"Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(6):e846-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36937/abstract-text/16291735/pubmed\" id=\"16291735\" target=\"_blank\">",
"        16291735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Purdy JB, Gafni RI, Reynolds JC, et al, \"Decreased Bone Mineral Density With Off-Label Use of Tenofovir in Children and Adolescents Infected With Human Immunodeficiency Virus,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2008, 152(4):582-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/4/36937/abstract-text/18346519/pubmed\" id=\"18346519\" target=\"_blank\">",
"        18346519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13012 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-BD52B341D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36937=[""].join("\n");
var outline_f36_4_36937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708727\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053105\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505100\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137430\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137461\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053167\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9848865\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137462\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137438\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137431\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053142\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137433\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6102646\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137434\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053147\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053146\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137437\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053111\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053112\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137463\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137459\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137460\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137465\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13012\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13012|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/25/23961?source=related_link\">",
"      Efavirenz, tenofovir, and emtricitabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/23/25973?source=related_link\">",
"      Efavirenz, tenofovir, and emtricitabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_4_36938="Pharmacology of azoles";
var content_f36_4_36938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of azoles",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36938/contributors\">",
"     Elizabeth Dodds Ashley, PharmD, MHS, BCPS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36938/contributors\">",
"     John R Perfect, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36938/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/4/36938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/4/36938/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/4/36938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Azole antifungal agents have added greatly to the therapeutic options for treatment of systemic fungal infections. The azoles that are available for systemic use can be classified into two groups: the triazoles (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ) and the imidazoles (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The use of azole agents for the treatment of various systemic fungal infections will be reviewed here. Other systemic antifungal agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , are discussed separately. The use of topical antifungals for onychomycosis and dermatophyte infections is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7082?source=see_link\">",
"     \"Dermatophyte (tinea) infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=see_link\">",
"     \"Onychomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Members of the triazole family are some of the most widely used antifungal agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/1\">",
"     1",
"    </a>",
"    ]. The drugs in this class offer activity against many fungal pathogens without the serious nephrotoxic effects observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . Newer azole agents have emerged as first-line therapies for several severe fungal diseases, such as invasive aspergillosis, for which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has become the standard of care.",
"   </p>",
"   <p>",
"    There are currently four members of the triazole class licensed for use in the United States (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Agents within the azole class vary importantly with regards to spectrum of activity, pharmacokinetic profiles, and toxicities. For example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    has excellent activity against yeasts, but offers no protection against molds. An extended spectrum is provided by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , but inconsistent bioavailability limits use of this agent in severely ill patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is the first-line agent for the treatment of invasive aspergillosis, but its bioavailability is unpredictable and genetically determined, it is associated with unique side effects, and lacks activity against the Mucorales, the agents of mucormycosis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    has the broadest spectrum of activity and fewest drug interactions, but absorption is problematic and it is available only as an oral formulation. Thus, it is important for clinicians to appreciate the unique characteristics of each member of this class in order to use azoles appropriately.",
"   </p>",
"   <p>",
"    The systemic use of earlier azoles, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , has largely been replaced by the triazoles because of superior pharmacokinetics, improved safety profiles, and higher efficacy for the treatment of systemic mycoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The azole antifungals work primarily by inhibiting the cytochrome P450 dependent enzyme lanosterol 14-alpha-demethylase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/2\">",
"     2",
"    </a>",
"    ]. This enzyme is necessary for the conversion of lanosterol to ergosterol, a vital component of the cellular membrane of fungi. Disruptions in the biosynthesis of ergosterol cause significant damage to the cell membrane by increasing its permeability, resulting in cell lysis and death. Despite this mechanism of action, the triazoles are generally considered fungistatic against Candida species. For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , fungicidal activity against Aspergillus species has been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGIC ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each member of the azole class exhibits a unique spectrum of activity, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    all demonstrate similar activity against most Candida species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/4\">",
"     4",
"    </a>",
"    ]. For detailed discussions of the clinical use of these agents, see the appropriate topic for specific fungal infections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      has activity limited to yeasts and some clinical activity against the endemic fungi (Histoplasma, Blastomyces, Coccidioides, and Paracoccidioides spp), although it is not as potent as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      for the endemic fungi. In general, it has excellent activity against Candida species, but has less activity against C. glabrata and no activity against C. krusei. It has excellent activity against Cryptococcus species.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      offers a broader spectrum of activity than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , including endemic fungi, Sporothrix schenckii, and Aspergillus species.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      has enhanced activity against Aspergillus species and other hyalohyphomycoses, including Scedosporium apiospermum and Fusarium species. Voriconazole also demonstrates superior activity in vitro against",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant C. glabrata and against C. krusei.",
"     </li>",
"     <li>",
"      The introduction of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      has expanded the spectrum of the azole agents further to include the Mucorales while maintaining activity against yeasts and molds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      is active against the endemic mycoses, dermatophytes, and Candida spp. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of clinical use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No two triazole agents offer the same pharmacokinetic profile. Understanding the differences among the members of this class with regards to metabolism and elimination is essential in order to safely and effectively administer these agents in the complex patient populations at risk for fungal infection. It is important to appreciate the differences in bioavailability, metabolism, and toxicities among these agents, as well as among different preparations of a given drug, since inconsistencies do exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available in both oral and intravenous preparations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is very hydrophilic and almost completely absorbed following oral administration; the reported bioavailability is over 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/7\">",
"     7",
"    </a>",
"    ]. Fluconazole's absorption is not affected by the presence of food or gastric pH. There is also an intravenous preparation, which is useful if gastrointestinal absorption or motility is impaired.",
"   </p>",
"   <p>",
"    A single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is widely distributed into body fluids and tissues, with only 10 to 12 percent being protein bound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/8\">",
"     8",
"    </a>",
"    ]. High concentrations can be measured in urine as well as prostatic tissues.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    distributes well into the cerebrospinal fluid (CSF), with levels reaching 60 to 80 percent of serum levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Fluconazole achieves concentrations in the vitreous body of 20 to 70 percent that in the serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long serum half-life (approximately 24 hours) allows once daily dosing.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is metabolized to a minimal extent; greater than 80 percent of a single dose is excreted unchanged in the urine. Thus, dose adjustments are necessary in patients with compromised renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is widely available as a capsule and an oral solution. An intravenous formulation, available in some countries, is no longer available in the United States.",
"   </p>",
"   <p>",
"    The bioavailability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is highly variable. The capsule formulation has a bioavailability of approximately 55 percent, whereas the bioavailability of the itraconazole solution (containing cyclodextrin), in fasting state is approximately 30 percent greater than with capsules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/13\">",
"     13",
"    </a>",
"    ]. Due to differences in bioavailability, the capsules and oral solution should not be used interchangeably and the solution is preferred. However, gastrointestinal upset is more common with the solution, and some patients cannot tolerate this formulation.",
"   </p>",
"   <p>",
"    The optimal conditions for administration of each formulation differ:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      capsules require food and an acidic gastric pH for solubilization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/14\">",
"       14",
"      </a>",
"      ]. Absorption can be increased by concurrent ingestion of cola [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/15,16\">",
"       15,16",
"      </a>",
"      ] or cranberry juice, and is impaired by drugs that interfere with gastric acidification. Impaired absorption is greatest with proton pump inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/17\">",
"       17",
"      </a>",
"      ], which should be avoided; intermediate with histamine H2 receptor blockers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/15,18,19\">",
"       15,18,19",
"      </a>",
"      ]; and least with antacids, which have a short duration of action.",
"     </li>",
"     <li>",
"      In contrast, the bioavailability of the oral solution is not altered by gastric pH. It should be administered on an empty stomach for optimal absorption; even in the presence of food, higher serum concentrations are achieved with the oral solution than with the capsule [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hydroxypropyl-beta-cyclodextrin is used to solubilize the IV and oral formulations. This vehicle is known to accumulate in patients with impaired renal function and therefore, use of the intravenous preparation is limited to patients with a creatinine clearance &gt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Since the cyclodextrin vehicle is not absorbed from the oral solution, patients should be converted to either oral formulation as soon as is feasible.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    has a relatively long half-life, approaching 25 to 50 hours, and thus allows for once daily dosing if using up to 200 mg daily. However, when 400 mg daily is required, dosing should be split into two divided doses to optimize absorption.",
"   </p>",
"   <p>",
"    Approximately 99 percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and its active hydroxy metabolite are bound to plasma proteins. Unbound itraconazole is highly lipophilic, and extensively distributed in human tissues, reaching high concentrations in the lungs, kidneys, and epidermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/21\">",
"     21",
"    </a>",
"    ]. High levels (greater than three times the corresponding serum levels) are observed in the skin, nails, liver, adipose tissue, and bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Only trace amounts are detected in the CSF and the eye.",
"   </p>",
"   <p>",
"    Metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is extensive in the liver (primarily via cytochrome P450 3A4), and excretion of inactive metabolites occurs primarily in the urine and feces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/24\">",
"     24",
"    </a>",
"    ]. A hepatic metabolite, hydroxyitraconazole, is bioactive, with activity similar to that of the parent compound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral tablet formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has a bioavailability of greater than 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"     26",
"    </a>",
"    ]. Oral bioavailability is reduced by approximately 30 percent when taken with a high fat meal. Administration on an empty stomach, one to two hours before or after a meal, is preferable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The powder for suspension possesses equivalent oral bioavailability compared with the tablet. The oral formulations do not contain cyclodextrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the intravenous preparation of voriconazole contains a sulfobutyl ether-beta-cyclodextrin vehicle, which is known to accumulate in patients with impaired renal function. Thus, use of the intravenous preparation is limited to patients who have CrCl &gt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    However, it should be noted that in severe infections requiring intravenous administration, the IV formulation of voriconazole has been safely used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is well distributed throughout the body as demonstrated by its large volume of distribution (4.6",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    and ability to penetrate into the CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. Voriconazole undergoes extensive hepatic metabolism by the cytochrome P450 enzyme system. The specific enzymes involved are CYP2C19, 2C9 and 3A4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"     26",
"    </a>",
"    ]. Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , there are no active metabolites. A 50 percent maintenance dose reduction, after a full loading dose, is recommended for patients with mild and moderate chronic hepatic insufficiency (Child-Pugh Classes A and B) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CYP2C19 gene polymorphisms appear to play an important role in the inter-individual variability that has been observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/30\">",
"     30",
"    </a>",
"    ]. Slow metabolizers via CYP2C19 (including 15 to 20 percent of persons of Asian descent) exhibit significantly greater systemic exposure and therefore should be considered at elevated risk of dose-related adverse effects such as hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Overview of CYP and other effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is also an inhibitor of cytochrome P450 3A4. Drug interactions should be anticipated and managed. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Less than 2 percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is excreted in the urine as unchanged drug. Thus, urine concentrations of voriconazole do not reach therapeutic levels and should",
"    <strong>",
"     not",
"    </strong>",
"    be relied upon to treat urinary tract infections. Dose adjustments of oral voriconazole are not necessary for patients with renal dysfunction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    exhibits non-linear pharmacokinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/31\">",
"     31",
"    </a>",
"    ]. Increasing the dose of voriconazole by 50 percent can lead to a 150 percent increase in serum concentration and a significant increase in serum half-life. This is important to consider because some voriconazole-associated toxicities are associated with higher serum concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Furthermore, higher doses of voriconazole have not been associated with improved clinical outcomes. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Voriconazole'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is available only as an oral suspension, pending development of an appropriate intravenous vehicle. Effective absorption of the drug requires oral intake, optimally with a high-fat meal, and it may be impaired in the setting of gastrointestinal tract disruption (eg, graft-versus-host disease or mucositis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Thus, it is recommended that each dose of posaconazole be given with a full meal or liquid nutritional supplement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    increase with more frequent administration. When given as four daily doses, total serum concentration was greater than when the same total amount of drug was divided into two doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/37\">",
"     37",
"    </a>",
"    ]. Absorption appears to saturate at a total daily dose of 800",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    so there is no added benefit from higher doses.",
"   </p>",
"   <p>",
"    The elimination half-life of the active (parent) compound is approximately 35 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/36\">",
"     36",
"    </a>",
"    ]. Approximately 14 percent of an administered dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    undergoes non-cytochrome 450 (CYP) hepatic metabolism to inactive metabolites and is excreted in urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/36,38\">",
"     36,38",
"    </a>",
"    ]. The unchanged parent drug is primarily eliminated via the fecal route (77 percent). Therefore, only minimal amounts are recovered in the urine and dose reductions are not required for patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/38\">",
"     38",
"    </a>",
"    ]. Posaconazole is an inhibitor of CYP3A4 metabolism and p-glycoprotein transport. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ketoconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    is available as an oral formulation and as a cream, gel, foam, and shampoo for topical use. Elimination is biphasic with a half-life of 2 hours within the first 10 hours and 8 hours thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/39\">",
"     39",
"    </a>",
"    ]. Approximately 13 percent of oral ketoconazole is excreted in the urine, of which only 2 to 4 percent is unchanged drug. The majority of the drug is excreted via the biliary system. Penetration into the CSF is poor.",
"   </p>",
"   <p>",
"    Absorption of the oral formulation is highly variable among individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/40\">",
"     40",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    requires an acidic gastric pH for optimal absorption. Absorption can be increased by administration with a cola beverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/41\">",
"     41",
"    </a>",
"    ], and is impaired by drugs that interfere with gastric acidification. The effect is greatest with proton pump inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/41\">",
"     41",
"    </a>",
"    ]; intermediate with H2 receptor blockers; and least with antacids or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    , which have a short duration of action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    is a potent inhibitor of CYP3A4 hepatic metabolism. Significant drug interactions should be anticipated and managed. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triazoles are generally well tolerated. Gastrointestinal symptoms are most frequently reported, including nausea, abdominal pain, vomiting and diarrhea. The latter is most notable with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    oral solution and is caused by the cyclodextrin vehicle, which enhances its solubility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/45\">",
"     45",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    also commonly causes GI distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic function abnormalities are associated with all of the azoles. These range from mild elevations in transaminases to severe hepatic reactions including hepatitis, cholestasis, and fulminant hepatic failure. The approximate incidence of mild transient transaminase abnormalities associated with azole drugs is reported to be from 2 to 12 percent. Hepatic inflammation may be exposure-related, especially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , but a clear dose or time course relationship is not well established. The toxicity is usually hepatocellular but may be cholestatic or both.",
"   </p>",
"   <p>",
"    Hepatic abnormalities necessitating drug discontinuation have been reported in less than 1 to 8 percent of patients in post-marketing experience and clinical trials. In most cases in which azole drug therapy was discontinued promptly following the emergence of abnormal transaminases, normalization of values and resolution of symptoms, if any, occurred gradually over weeks. Close monitoring of transaminases is recommended, and particularly in the first weeks and months of therapy. The decision to stop azoles when transaminase elevations occur is made by the clinician determining the risks versus the benefits for each patient.",
"   </p>",
"   <p>",
"    Careful monitoring of liver enzymes is recommended for all patients receiving azole therapy, since this adverse effect does not appear to be associated with duration of antifungal therapy or other identifiable risk factors. High-dose therapy, drug interactions, and genetic polymorphisms that increase systemic exposure to azoles, may increase the risk of hepatotoxicity. While the majority of cases of hepatic toxicity resolve after discontinuation of therapy, fatal events have been reported with each agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drug-specific adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the azoles carries a unique side effect profile, in addition to those seen with the entire class. Some of these are discussed briefly below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alopecia and chapped lips have been reported following long courses of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/46\">",
"     46",
"    </a>",
"    ]. These conditions are reversible after discontinuation of the agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    can cause a triad of hypertension, hypokalemia, and peripheral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/47\">",
"     47",
"    </a>",
"    ]. Cases of heart failure have been described in patients receiving itraconazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/48\">",
"     48",
"    </a>",
"    ]. This agent should not be used for the treatment of simple conditions, such as onychomycosis, in patients with evidence of ventricular dysfunction or with a history of congestive heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cyclodextrin vehicle that is used to solubilize the oral solution can cause gastrointestinal distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is associated with several unique adverse reactions; these include transient vision changes, a photosensitivity rash, and periostitis, which is seen only in those on long-term voriconazole therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vision changes &mdash;",
"      </strong>",
"      Among 1655 patients included in trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , abnormal vision, including photopsia or flashes of light, was reported in 19 percent, photophobia in 2 percent, and color changes in 1 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"       26",
"      </a>",
"      ]. These transient effects are temporally associated with drug dosing, occurring within 30 minutes of oral or intravenous administration. Symptoms usually last for approximately 30 to 60 minutes, but in some patients can be prolonged for hours. Clinical trials suggest that visual abnormalities may be associated with higher dosing or serum concentrations. These effects generally subside with continued therapy over several weeks. Counseling patients regarding potential effects on operating a motor vehicle is warranted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26,49\">",
"       26,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic toxicity &mdash;",
"      </strong>",
"      A serious adverse effect that must be distinguished from minor vision changes, such as photopsia, is that of visual hallucinations which represent neurologic toxicity that has been linked to serum concentrations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      &gt;5.5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/33\">",
"       33",
"      </a>",
"      ]. In addition to visual hallucinations, patients with neurologic toxicity may also have confusion, agitation, myoclonic movements, and auditory hallucinations. These effects disappear when the serum concentration is lowered to &lt;5.5",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      Some patients, even when they have appropriate serum levels, complain of having trouble thinking, an inability to focus on a task, or just not seeming themselves for several hours after taking voriconazole.",
"      <br/>",
"      <br/>",
"      An extremely rare adverse event is peripheral demyelinating neuropathy of the lower extremities, reported mostly in transplant recipients who are also taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Skin toxicity &mdash;",
"      </strong>",
"      A rash associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      therapy was reported in approximately 7 percent of patients enrolled in clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"       26",
"      </a>",
"      ]. One type of rash seen with voriconazole is a photosensitivity reaction. Sun avoidance should be encouraged in patients who have experienced photosensitivity reactions during voriconazole therapy. The rash has precipitated discontinuation of voriconazole and abates with withdrawal of therapy. Rare cases of severe rash (Stevens-Johnson syndrome, toxic epidermal necrolysis) have also been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"       26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      An association has been observed between long-term use of voriconazole and the development of skin cancers, mostly squamous cell carcinomas, but also melanomas; clinicians should therefore examine patients on long-term voriconazole for concerning skin lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/51-55\">",
"       51-55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Periostitis &mdash;",
"      </strong>",
"      Periostitis is an adverse event that has been observed in patients who have been taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      for many months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/56-58\">",
"       56-58",
"      </a>",
"      ]. It appears to be due to fluoride excess and typically presents as bone pain, elevated alkaline phosphatase, and characteristic findings along the periosteum of affected bones on plain radiographs and bone scans. The US Food and Drug Administration recommends that voriconazole be discontinued in patients who develop skeletal pain and radiologic findings compatible with fluorosis or periostitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/59\">",
"       59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A case-control study and detailed analysis of serum fluoride concentrations in transplant patients on long-term voriconazole showed a significant correlation between fluoride levels and voriconazole use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/57\">",
"       57",
"      </a>",
"      ]. Among three allogeneic hematopoietic cell transplant recipients who developed periostitis during long-term voriconazole use, cessation of treatment resulted in clinical improvement in all cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/58\">",
"       58",
"      </a>",
"      ]. Clinically relevant periostitis was associated with renal insufficiency and with substantial elevations in serum fluoride concentration. Two patients who developed clinically relevant periostitis had serum fluoride concentrations that were &gt;10-fold higher (316",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      and 363",
"      <span class=\"nowrap\">",
"       mcg/L)",
"      </span>",
"      than normal concentrations (&lt;30",
"      <span class=\"nowrap\">",
"       mcg/L).",
"      </span>",
"      The median serum fluoride concentration in 20 patients receiving long-term voriconazole was 157",
"      <span class=\"nowrap\">",
"       mcg/L.",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac toxicity &mdash;",
"      </strong>",
"      Cases of QT prolongation, torsades de pointes, cardiac arrest, and sudden death have been reported in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26,60,61\">",
"       26,60,61",
"      </a>",
"      ]. These adverse effects were reported in severely ill patients with multiple comorbidities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concomitant use of other drugs that also could have prolonged the QT interval.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been concern about the potential for nephrotoxicity of IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in patients with renal dysfunction because the IV formulation contains sulphobutylether-beta-cyclodextrin (SBECD); SBECD is a solubilizing agent that is renally cleared and that has been associated with nephrotoxicity in rats as a result of renal tubule vacuolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The manufacturer has recommended that IV voriconazole be avoided in patients with renal insufficiency (CrCl &lt;50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"     26",
"    </a>",
"    ]. However, in a retrospective study that evaluated renal function in 166 patients receiving IV or oral voriconazole (one-quarter of whom had a glomerular filtration rate &lt;50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at baseline and received IV voriconazole), neither baseline renal function nor route of administration was associated with worsening renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/28\">",
"     28",
"    </a>",
"    ]. Limitations of this study are that it was a small study and that few patients received voriconazole for &ge;7 days; it is possible that a longer duration of therapy in patients with preexisting renal dysfunction is more nephrotoxic than a shorter course. Further study is necessary to determine whether IV voriconazole is nephrotoxic in patients with preexisting renal dysfunction. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Voriconazole'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available data suggest that the adverse effect profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    is more favorable than other triazoles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/49\">",
"     49",
"    </a>",
"    ]. Gastrointestinal symptoms are frequent. A case of torsades de pointes has been reported in a patient who was taking posaconazole, although no QTc prolongation was observed in healthy volunteers receiving posaconazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. Incidence of QTc prolongation was described as occurring in 1 percent of 428 patients treated for febrile neutropenia or refractory invasive fungal infection in phase II and III clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/49\">",
"     49",
"    </a>",
"    ] and 4 percent in comparative trials with other azoles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ketoconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    causes more gastrointestinal intolerance than the other azoles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/39\">",
"     39",
"    </a>",
"    ]. Like the other azoles, oral ketoconazole can also cause hepatitis. Other adverse effects include headaches, dizziness, and pruritus.",
"   </p>",
"   <p>",
"    Applied topically, severe irritation, pruritus and stinging occur commonly. Abnormal hair loss,",
"    <span class=\"nowrap\">",
"     dry/oily",
"    </span>",
"    scalp or itching may be seen following the application of the shampoo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have noted an association between prolonged",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    use in pregnant women and craniofacial and other abnormalities in their newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. In 2011, the US Food and Drug Administration (FDA) changed the pregnancy category for fluconazole (for indications other than vaginal candidiasis) from C to D; the use of a single dose of 150 mg of fluconazole for vaginal candidiasis continues to be pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/69\">",
"     69",
"    </a>",
"    ]. The change from pregnancy class C to D was based upon several published reports of birth defects in infants whose mothers received high-dose fluconazole (400 to 800 mg per day) for serious fungal infections during most or all of the first trimester. The birth defects observed in these infants included a short broad head, an abnormal looking face, abnormal development of the skullcap, cleft lip or palate, bowing of the thigh bones, thin ribs and long bones, muscle weakness, joint deformities, and congenital heart disease.",
"   </p>",
"   <p>",
"    On the other hand, several epidemiologic studies that focused on low-dose, short course therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    did not detect an increased risk of congenital malformations among the offspring of women who took fluconazole during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. The largest of these studies, a population-based cohort study of 1079 women who took fluconazole during the first trimester of pregnancy, found no increase in the incidence of congenital malformations after fluconazole exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/71\">",
"     71",
"    </a>",
"    ]. The authors noted that their sample size was insufficient for examining risks of specific birth defects.",
"   </p>",
"   <p>",
"    This study, as well as others that focused on low-dose, short duration therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used to justify fluconazole use in pregnancy, especially during the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small cohort study of short-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    use during pregnancy did not show an increased incidence of congenital abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/74\">",
"     74",
"    </a>",
"    ]. No studies have been performed with the other triazoles in pregnant women. Nevertheless, we recommend avoiding all azoles during pregnancy, especially during the first trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doses of the triazoles are chosen depending upon the severity of the infection being treated and the formulation being used. The clinician is advised to consult individual topics for each infection for more detailed information on the use of specific drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    depends upon the indication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oropharyngeal candidiasis: 200 mg loading dose, then 100 to 200 mg daily for 7 to 14 days (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"       \"Treatment of oropharyngeal and esophageal candidiasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Esophageal candidiasis: 400 mg loading dose, then 200 to 400 mg daily for 14 to 21 days (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"       \"Treatment of oropharyngeal and esophageal candidiasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vaginal candidiasis: 150 mg (1 dose only) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15386?source=see_link\">",
"       \"Candida vulvovaginitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Candidal urinary tract infections: 200 mg daily for 14 days (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=see_link\">",
"       \"Candida infections of the bladder and kidneys\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cryptococcal meningitis (IV or orally): following induction therapy, 400 mg daily as consolidation dose; then 200 mg daily as maintenance dose (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15210?source=see_link\">",
"       \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Histoplasmosis/blastomycosis/coccidioidomycosis:",
"      </span>",
"      400 to 800 mg orally daily (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=see_link\">",
"       \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=see_link\">",
"       \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29912?source=see_link\">",
"       \"Treatment of blastomycosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=see_link\">",
"       \"Primary coccidioidal infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17271?source=see_link\">",
"       \"Coccidioidal meningitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21848?source=see_link\">",
"       \"Coccidioidomycosis in compromised hosts\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26807?source=see_link\">",
"       \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Candidemia/Invasive",
"      </span>",
"      candidiasis (IV or orally): 800 mg loading dose followed by 400 mg daily (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A loading dose, twice that of the maintenance dose, is usually administered on the first day of therapy for severe infections. In addition, even higher doses have been used in specific clinical scenarios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/8,75\">",
"     8,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the excellent bioavailability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , equivalent doses of the oral and intravenous formulations are used. Fluconazole should be given orally whenever feasible.",
"   </p>",
"   <p>",
"    Doses need to be adjusted for patients with renal dysfunction. The following dose reductions are recommended, according to estimated creatinine clearance (CrCl) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CrCl: 20-50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      reduce the dose by 50 percent",
"     </li>",
"     <li>",
"      CrCl: &lt;20",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      reduce the dose by 75 percent",
"     </li>",
"     <li>",
"      Hemodialysis: 100 percent of indicated dose after each hemodialysis treatment only",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    depends upon the indication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oropharyngeal or esophageal candidiasis: 200 mg of the solution daily (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"       \"Treatment of oropharyngeal and esophageal candidiasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Histoplasmosis/blastomycosis:",
"      </span>",
"      200 to 400 mg daily (in two divided doses if the higher dosing is used) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=see_link\">",
"       \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=see_link\">",
"       \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29912?source=see_link\">",
"       \"Treatment of blastomycosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coccidioidomycosis: 200 mg two or three times daily (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=see_link\">",
"       \"Primary coccidioidal infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17271?source=see_link\">",
"       \"Coccidioidal meningitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21848?source=see_link\">",
"       \"Coccidioidomycosis in compromised hosts\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26807?source=see_link\">",
"       \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Allergic bronchopulmonary aspergillosis: 200 mg twice daily (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"       \"Allergic bronchopulmonary aspergillosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Onychomycosis (toenails): 200 mg daily for 12 weeks or pulse therapy",
"     </li>",
"     <li>",
"      Onychomycosis (fingernails): 200 mg twice daily for one week (repeat course after three-week drug holiday) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=see_link\">",
"       \"Onychomycosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total daily oral doses of 400 mg or greater should always be given in divided doses to increase bioavailability. A loading dose is administered as 200 mg three times daily for three days followed by 200 mg once or twice daily.",
"   </p>",
"   <p>",
"    Dosing of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    does not need to be modified in patients with renal insufficiency since the drug is metabolized in the liver. Data on the appropriate dosing of itraconazole in patients with hepatic insufficiency are not available, but this agent should be used with caution in this setting. Neither hemodialysis nor peritoneal dialysis alters serum levels of itraconazole.",
"   </p>",
"   <p>",
"    The liquid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , given in the same dosages noted above, overcomes problems caused by poor absorption of the capsule and the same dose achieves approximately 30 percent higher concentrations in the serum. The solution should be given on an empty stomach to obtain the highest serum concentrations. However, more gastrointestinal upset occurs with the solution formulation, which precludes its use in some patients.",
"   </p>",
"   <p>",
"    The use of the intravenous preparation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is limited by the cyclodextrin vehicle. It is only recommended for use in patients with a creatinine clearance &gt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and is usually reserved for patients with severe infections who are intolerant of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The intravenous formulation is no longer marketed in the United States and existing stocks expired in 2008.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    injection may remain available outside of the US. Dosing of the intravenous preparation, independent of the indication, is as follows: 200 mg IV every 12 hours (for four doses); then 200 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both intravenous and oral formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    require a loading dose at the initiation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loading Dose:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravenous: 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours for two doses",
"     </li>",
"     <li>",
"      Oral: 400 mg every 12 hours for two doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maintenance Dose:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravenous: 3 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours",
"     </li>",
"     <li>",
"      Oral: 200 mg every 12 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to the prescribing information, patients who are not responsive to initial therapy or who have more resistant pathogens, the oral dose may be increased to 300 mg every 12 hours.",
"   </p>",
"   <p>",
"    Dosing practices for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    that promote weight-based dosing for the intravenous preparation and fixed dosing for the oral formulation have long been questioned by practitioners. Many experts in this area promote weight-based dosing independent of the formulation being used although a prospective evaluation comparing this method with oral dosing of voriconazole is lacking.",
"   </p>",
"   <p>",
"    In a study of the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    that examined more than 500 voriconazole serum trough concentrations from 55 patients, it was suggested that current oral dosing recommendations may in fact be inadequate for some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/76\">",
"     76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using population-based simulations with the recommended oral dose of 200 mg twice daily, the predicted probability of achieving a serum trough concentration of 1.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      was 49 percent, and the predicted probability of achieving a serum trough concentration of 4.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      was 8 percent.",
"     </li>",
"     <li>",
"      With an oral dose of 300 to 400 mg twice daily, the predicted probabilities of achieving a serum trough concentration of 1.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      were 68 to 78 percent, and the predicted probabilities of achieving a serum trough concentration of 4.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      were 19 to 29 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that the same study predicted that IV dosing of 200 or 300 mg twice daily also resulted in suboptimal concentrations in some patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With an IV dose of 200 to 300 mg twice daily, the predicted probabilities of achieving a serum trough concentration of 1.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      were 70 to 87 percent, and the probabilities of achieving a serum trough concentration of 4.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      were 18 to 37 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous therapy should be avoided, unless required for treatment of severe infection, in patients with renal insufficiency (CrCl &lt;50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    due to accumulation of the cyclodextrin vehicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Voriconazole'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Either oral formulation (tablet or suspension) should be administered on an empty stomach. Bioavailability decreases if given with food, especially fatty food. In addition, dose adjustments are required for patients weighing less than 40 kg and those receiving concomitant interacting medications (see",
"    <a class=\"local\" href=\"#H31\">",
"     'Drug interactions'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The issue of dosing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in obese patients is complex and not fully understood. Given the non-linear pharmacokinetics of this agent, dose escalation may result in an increased risk of toxicity, whereas underdosing may result in inadequate concentrations. In a study of oral dosing regimens in obese patients (median weight 133 kg, median BMI 46.2",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    a fixed oral dose of 200 mg every 12 hours resulted in similar drug exposure compared with non-obese individuals (median weight 76.9 kg, median BMI 23.7",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/77\">",
"     77",
"    </a>",
"    ]. These data suggest that dosing adjustments are not required in obese subjects receiving oral treatment.",
"   </p>",
"   <p>",
"    The weight-based dosing regimens for the IV formulation pose further challenges in obese patients. The prescribing information suggests using total body weight with recommendations only for those patients weighing up to 100 kg, without providing guidance for subjects with higher body weight. In a study that evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    concentrations among obese patients receiving weight-based dosing, those whose dosing was determined using adjusted body weight had an 80 percent likelihood of concentrations within the therapeutic range (2 to 5.5",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    compared with a 45 percent likelihood using ideal body weight and a 29 percent likelihood using total body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/78\">",
"     78",
"    </a>",
"    ]. Therefore, many clinicians recommend using an adjusted body weight ([actual weight &ndash; ideal weight] 0.4 + ideal weight) when dosing IV voriconazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    depends on the indication.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylaxis of invasive fungal infections in patients with acute leukemia undergoing induction chemotherapy and hematopoietic cell transplant recipients who have severe graft-versus-host disease: 200 mg three times daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/79-81\">",
"       79-81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oropharyngeal candidiasis: Loading dose of 100 mg twice daily on the first day; then 100 mg once a day for 13 days.",
"     </li>",
"     <li>",
"      Oropharyngeal candidiasis refractory to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      : 400 mg twice daily. Duration of therapy should be based upon the patient's clinical response. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"       \"Treatment of oropharyngeal and esophageal candidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For salvage therapy for mucormycosis or other invasive fungal infections: Ideally, 200 mg orally four times daily with fatty food or, in patients who are unable to take the solution four times daily, 400 mg orally twice daily with fatty food [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/35,37\">",
"       35,37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=see_link&amp;anchor=H20#H20\">",
"       \"Mucormycosis (zygomycosis)\", section on 'Antifungal drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ketoconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    has been largely replaced by the newer azoles described above, given their favorable pharmacokinetics and safety profiles, and improved efficacy for the treatment of systemic mycoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SERUM DRUG CONCENTRATION MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many centers, it has become standard of care to monitor serum azole concentrations. Guidelines are available for recommended",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    concentrations when this agent is used for the treatment of certain invasive fungal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Measurement of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    serum concentrations is increasingly performed to assure efficacy in the treatment of serious fungal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/33,85-88\">",
"     33,85-88",
"    </a>",
"    ] and, in the case of voriconazole, to avoid toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the unpredictable absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , the Infectious Diseases Society of America guidelines recommend monitoring serum levels in patients receiving itraconazole for the treatment of aspergillosis, histoplasmosis, or blastomycosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29912?source=see_link\">",
"     \"Treatment of blastomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum concentrations should be tested only after steady-state has been achieved (after two weeks of therapy). By waiting until this point, a random concentration is sufficient and is much more convenient than a peak concentration for patients being seen in the ambulatory setting.",
"   </p>",
"   <p>",
"    Serum concentrations are useful in determining whether or not individuals are absorbing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , but also provide information when drug-drug interactions might be a problem and help define whether the patient is compliant with their medications. It is recommended that the measured serum itraconazole concentration for the treatment of invasive fungal infections, such as histoplasmosis and blastomycosis, should be at least 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    by high-performance liquid chromatography (HPLC) and 3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    by bioassay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    activity is due not only to the parent drug, but also to its active metabolite, hydroxyitraconazole. Two common techniques for measuring itraconazole concentrations handle this factor differently:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HPLC measures the quantity of each component separately. Most laboratories run HPLC assays for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      and hydroxyitraconazole concurrently and the results of both tests should be considered when attempting to evaluate clinical activity. Many would advocate adding these two results together to get a sum of itraconazole activity, although this is not uniformly done.",
"     </li>",
"     <li>",
"      In contrast to HPLC, bioassay results represent the amount of both the parent drug and the active metabolite.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      concentrations measured by bioassay can be 2- to 10-fold higher than those obtained by HPLC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/89,90\">",
"       89,90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A concentration-effect relationship between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    levels and toxicity has been identified. In patients receiving itraconazole, concentrations &gt;17.1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    as measured by bioassay were associated with a high probability of toxicity (86 percent), whereas concentrations &lt;17.1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    were associated with a low probability of toxicity (31 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/91\">",
"     91",
"    </a>",
"    ]. The majority of patients were being treated for either chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis. Thus, these results may not be applicable to immunocompromised patients with invasive fungal infections who may be at higher risk of toxicity due to the use of multiple agents and who also may not absorb the drug well enough to attain levels this high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial variability in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    serum drug concentrations in patients receiving standard oral dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/33,85,87,92,93\">",
"     33,85,87,92,93",
"    </a>",
"    ]. Studies have correlated higher failure rates with low serum voriconazole concentrations, and adequate levels with favorable response. In addition, higher concentrations are associated with neurotoxicity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    trough concentrations should be checked four to seven days into therapy for all patients who are receiving treatment for invasive fungal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/88\">",
"     88",
"    </a>",
"    ]. Although debate remains over the optimal target concentration, available data suggest a therapeutic range of greater than 1",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    and less than 5.5",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    Trough concentrations below 1",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    warrants an increase in the voriconazole dose and appropriate subsequent monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/33\">",
"     33",
"    </a>",
"    ]. On the other hand, serum drug concentrations above 5.5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    warrant a reduction in the voriconazole dose, since they have been associated with an increased risk of toxicity without documented clinical benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/33,94\">",
"     33,94",
"    </a>",
"    ]. It is important to note that decisions about dose modification based upon voriconazole concentrations must always be made within the context of the clinical status of the patient, which is the most essential element in determining what, if any, dose modification is appropriate.",
"   </p>",
"   <p>",
"    The importance of appropriate serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    concentrations has been illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 52 patients who were serially monitored with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      trough concentrations, among six nonresponding patients who also had low trough concentrations (less than 1",
"      <span class=\"nowrap\">",
"       mcg/mL),",
"      </span>",
"      clinical improvement was seen following an increase in voriconazole dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/33\">",
"       33",
"      </a>",
"      ]. However, 5 of 16 patients (31 percent) with serum voriconazole concentrations above 5.5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      developed encephalopathy.",
"     </li>",
"     <li>",
"      In a population pharmacokinetic analysis that was performed on 505 plasma concentration measurements from 55 patients, using multivariate analysis, an association was observed between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      trough concentration and probability of response or neurotoxicity by identifying a therapeutic range of 1.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (&gt;85 percent probability of response) to 4.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (&lt;15 percent probability of neurotoxicity) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/76\">",
"       76",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Voriconazole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A randomized trial was performed to evaluate the effect of serum concentration monitoring on the safety and efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      in 110 adults being treated for invasive fungal infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/95\">",
"       95",
"      </a>",
"      ]. Patients were randomly assigned to undergo or not undergo serum concentration monitoring. Among the patients who underwent serum concentration monitoring, the voriconazole dose was adjusted (target range 1.0 to 5.5",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      according to the serum trough concentration measured on the fourth day of therapy. Although the incidence of adverse effects was the same in both groups (42 percent), the proportion of voriconazole discontinuation due to adverse effects was significantly lower in the group that underwent monitoring compared with the group that did not undergo monitoring (4 versus 17 percent). Furthermore, a complete or partial response was observed significantly more frequently in the group that underwent monitoring (81 versus 57 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum drug concentration monitoring of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is rarely performed. The reliable bioavailability and benign toxicity profile of this agent obviate the need to measure serum concentrations in nearly all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no guidelines for monitoring serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    concentrations. However, studies have suggested a relationship between posaconazole concentrations and both prophylactic efficacy and response rates for invasive aspergillosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/96-98\">",
"     96-98",
"    </a>",
"    ], and other invasive fungal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/99\">",
"     99",
"    </a>",
"    ]. Thus, in patients with serious infections such as invasive aspergillosis, monitoring serum concentrations is recommended, especially given that the absorption of posaconazole is dependent upon its administration with a fatty meal.",
"   </p>",
"   <p>",
"    Furthermore, absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    is highly variable in hematopoietic cell transplant recipients, especially those with acute graft-versus-host-disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/34\">",
"     34",
"    </a>",
"    ]. Among patients with hematologic malignancies receiving posaconazole prophylaxis, mucositis and lower caloric intake were independently associated with reduced posaconazole concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Also, given reports concerning drug-drug interactions between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    and proton pump inhibitors, clinicians should monitor serum concentrations in patients receiving posaconazole concomitantly with drugs that increase the gastric pH, such as proton pump inhibitors, since these agents can result in decreased serum posaconazole concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Based upon the limited data available, if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    concentration monitoring is desired, trough concentrations should be obtained after four to seven days of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/88\">",
"     88",
"    </a>",
"    ]. We suggest a trough concentration &ge;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for prophylaxis, and &ge;0.7",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for the treatment of severe infections. A study of patients with invasive fungal infections refractory to other agents has shown that higher drug concentrations are associated with improved clinical responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major drug-drug interactions associated with the azole antifungal agents involve oxidative drug metabolism via the cytochrome P450 enzyme system. All azole agents are both metabolized by and affect the hepatic cytochrome P450 (CYP) enzymes to varying degrees (",
"    <a class=\"graphic graphic_table graphicRef66477 \" href=\"mobipreview.htm?8/51/9021\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/20,101\">",
"     20,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Overview of CYP and other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is a strong inhibitor of CYP2C19 and 2C9, a moderate inhibitor of CYP3A4, and a substrate of p-glycoprotein. It is also an inhibitor of uridine 5'-diphosphate glucuronosyltransferases (UGT) enzymes. This is generally not a concern for doses &lt;200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/101\">",
"     101",
"    </a>",
"    ]. Fluconazole is only a weak substrate of CYP450 enzymes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is a strong inhibitor of CYP3A4. It is also a substrate of CYP3A4, and a substrate and inhibitor of p-glycoprotein.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is a moderate inhibitor of CYP3A4. It is a weak inhibitor of CYP2C19 and 2C9 isoenzymes. Voriconazole is metabolized extensively by CYP2C19 and CYP3A4, and to a lesser extent by CYP2C9. Since CYP2C9 and CYP2C19 exhibit genetic polymorphism, wide variations in pharmacokinetics are observed among certain patient populations (ie, 15 to 20 percent of Asian populations and 3 to 5 percent of others who are poor metabolizers via this mechanism will have significantly elevated serum concentrations) (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Voriconazole'",
"    </a>",
"    above). Voriconazole does not appear to be a substrate or inhibitor of p-glycoprotein.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is an inhibitor of CYP3A4. Posaconazole is not metabolized via the P450 enzyme system, but is primarily metabolized by UDP glucuronidation, and is a substrate and inhibitor of p-glycoprotein. Drug-drug interactions similar to those seen with other inhibitors of CYP3A4 can occur.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    is a strong inhibitor of CYP3A4, a moderate inhibitor of CYP1A2, 2A6, and 2E1, and a substrate and inhibitor of p-glycoprotein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/20,102\">",
"     20,102",
"    </a>",
"    ]. Ketoconazole is largely metabolized by the hepatic enzyme, CYP3A4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Major drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive lists of the drug interactions that can occur are presented separately. The major interactions will be briefly reviewed here (",
"    <a class=\"graphic graphic_table graphicRef66477 \" href=\"mobipreview.htm?8/51/9021\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55886 \" href=\"mobipreview.htm?3/6/3181\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/17/34069?source=see_link\">",
"     \"Itraconazole: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/4/29765?source=see_link\">",
"     \"Fluconazole: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/60/12234?source=see_link\">",
"     \"Voriconazole: Pediatric drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/18/35112?source=see_link\">",
"     \"Posaconazole: Pediatric drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/52/38720?source=see_link\">",
"     \"Ketoconazole: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, specific interactions of azole agents with other medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CYP induction &mdash; In general, medications that induce hepatic CYP enzymes (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ) can accelerate the metabolism of the azoles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/103\">",
"       103",
"      </a>",
"      ]. Enzyme induction can require over up to two weeks to achieve maximum effect, and persists up to two weeks after discontinuation of the interacting medication, potentially delaying the response to treatment or causing treatment failure. If one of the other hepatic CYP inducers must be given concurrently, serum concentration monitoring of the azole agent is essential.",
"      <br/>",
"      <br/>",
"      Rifampin has the greatest effect; it has been associated with undetectable levels of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      in the serum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/103,104\">",
"       103,104",
"      </a>",
"      ] and significant decreases in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26,105-107\">",
"       26,105-107",
"      </a>",
"      ]. Concomitant use of rifampin is contraindicated with voriconazole, discouraged with itraconazole, and may warrant dose increases of fluconazole. Rifabutin may affect the azole agents to a lesser degree [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/102\">",
"       102",
"      </a>",
"      ]. Although no data are available specifically for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      and rifampin, data with rifabutin suggest that similar precautions are warranted with posaconazole and any of the rifamycins.",
"      <br/>",
"      <br/>",
"      The anticonvulsants also have significant effects on the azole agents. Carbamazepine is contraindicated with voriconazole due to the potential to significantly decrease serum concentrations of the azole; a similar effect is possible with itraconazole and ketoconazole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/108\">",
"       108",
"      </a>",
"      ]. Voriconazole, itraconazole, posaconazole, and ketoconazole exposure is decreased with phenytoin administration. The use of phenytoin with voriconazole requires an increase in voriconazole dosing to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours for the IV preparation and 400 mg every 12 h for oral administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CYP inhibition &mdash; A significant CYP interaction should be anticipated when an azole exerts a strong inhibitory effect on an isoenzyme that is the major metabolism pathway for another drug being taken by the patient. This is particularly important if the concomitant drug has a narrow therapeutic index. As an example, the combined use of azoles (particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      leads to an increase in the prothrombin time due to inhibition of CYP2C9 by the azole. CYP2C9 is the primary enzyme by which s-warfarin, the active form, is metabolized. Thus, dose reduction of warfarin is necessary when used in combination with azoles, and monitoring of INR around the time of azole initiation is recommended. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H16#H16\">",
"       \"Therapeutic use of warfarin\", section on 'Drug interactions'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       Posaconazole",
"      </a>",
"      has been found to increase the plasma concentration and area under the plasma concentration-time curve (AUC) of the HIV protease inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      , when used in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      via CYP3A4 inhibition; this was associated with increased serum total bilirubin concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      P-glycoprotein interactions &mdash; P-glycoprotein (P-GP) is an important drug efflux transporter found throughout the gastrointestinal tract. P-GP substrates are structurally similar to substrates of CYP-3A4, and many CYP-3A4 inhibitors also inhibit P-GP. Therefore, there is a potential for interactions via P-GP and the azole antifungals. However, determining the specific contribution of P-GP to a drug-drug interaction can be difficult.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      are known P-GP substrates, and itraconazole is a P-GP inhibitor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/20,36\">",
"       20,36",
"      </a>",
"      ]. One of the best characterized interactions via P-GP and azole antifungals is increased exposure of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      when given with itraconazole.",
"     </li>",
"     <li>",
"      Chelation with divalent cations or alterations in gastric pH &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      tablets,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      solution, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      capsules require gastric acidity for oral absorption. Drugs that increase gastric pH, including histamine-2 receptor antagonists, proton pump inhibitors, and antacids decrease serum levels of ketoconazole, posaconazole, and the capsule formulation of itraconazole, but not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      or the liquid formulation of itraconazole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/102,110-112\">",
"       102,110-112",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Itraconazole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      UGT pathway &mdash; Although less well studied than the interactions described above, a number of drugs utilize the uridine 5'-diphosphate glucuronosyltransferases (UGT; glucuronidation) pathway, which may also be affected by the azoles. An example is the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      interaction, which significantly reduces posaconazole exposure and increases phenytoin concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/20,36\">",
"       20,36",
"      </a>",
"      ]. Although CYP3A4 interactions probably play a part in this interaction, the increase in posaconazole clearance may result from induction of UGT by phenytoin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Selected clinical effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are some of the serious toxicities that can occur; such interacting drugs should be avoided, if possible, in patients treated with an azole (",
"    <a class=\"graphic graphic_table graphicRef66477 \" href=\"mobipreview.htm?8/51/9021\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55886 \" href=\"mobipreview.htm?3/6/3181\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long QT syndrome and possible sudden cardiac death due to torsade de pointes with concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , cisapride (which has limited availability),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      , or other agents that prolong the QT interval. As an example, all of the azoles except for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      delay haloperidol metabolism by CYP3A4 and both drug classes can prolong the QT interval in an exposure-related manner. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"       \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excessive sedation with concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/49/23319?source=see_link\">",
"       triazolam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      . A benzodiazepine that is not metabolized by CYP3A4, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      , is preferred.",
"     </li>",
"     <li>",
"      Rhabdomyolysis with coadministration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , which are metabolized by cytochrome P450 3A4. Inhibition of metabolism by azole antifungals results in increased plasma concentrations of the statin drugs. Coadministration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      with simvastatin, lovastatin, or atorvastatin is contraindicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/113\">",
"       113",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      , which are not metabolized by CYP3A4, are preferred during azole therapy, but if statins can be avoided while on azole therapy, that is preferred. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"       \"Statin myopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum concentrations and toxicities of a number of other drugs metabolized by CYP can be increased by azole therapy. These include HIV protease inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , some hypoglycemic agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Patients taking these medications must be monitored appropriately and empiric dose adjustments are often necessary.",
"   </p>",
"   <p>",
"    Combinations that deserve particular attention because of the frequent need for azoles in transplant recipients are the interactions between the azoles and immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and the calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    increases",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    levels by approximately 10-fold and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    increases sirolimus levels by approximately 8-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/26,36\">",
"     26,36",
"    </a>",
"    ]. This has led to the prescribing information for both voriconazole and posaconazole suggesting that sirolimus be avoided in patients receiving these agents. However, clinicians have sometimes coadministered these agents when clinically necessary. This practice can occur safely if the dose of sirolimus is reduced and sirolimus concentrations are monitored closely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Doses of sirolimus have been reduced empirically by up to 90 percent when voriconazole is added [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Any change in sirolimus dose needs to include a careful review of multiple factors, including sirolimus concentration at the time of azole initiation as well the individual patient's immunosuppressive requirements. Studies are ongoing regarding specific dosing algorithms based on baseline sirolimus concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/4/36938/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose reductions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are also necessary when used in combination with azoles. Although significant interpatient variability is seen, current recommendations are to decrease tacrolimus doses to one-third of the total daily dose when administered with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    . Recommendations for cyclosporine differ from a 50 percent reduction when voriconazole is added to 25 percent when posaconazole is added. Less clear recommendations exist for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . Regardless of the specific azole used, close monitoring of immunosuppressant concentrations following the addition or discontinuation of azole therapy is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The triazole family includes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      , which have activity against many fungal pathogens without the serious nephrotoxic effects observed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      administration. The agents within this class vary importantly with regards to clinical activity, pharmacokinetic profiles and toxicities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The azoles cause significant damage to the cell membrane by increasing its permeability, resulting in cell lysis and death. Despite this mechanism of action, the azoles are generally considered fungistatic against Candida species;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      is fungicidal against Aspergillus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Understanding the differences among the members of this class with regards to absorption, metabolism, and elimination is essential in order to safely and effectively administer these agents in complex patient populations. Oral bioavailability of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      is excellent, but",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      require special circumstances for maximum absorption. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Triazoles are generally well tolerated. Gastrointestinal symptoms are most frequently reported. Gastrointestinal intolerance is most common with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      . Serious hepatotoxicity has been reported with the azoles, so monitoring of aminotransferases is recommended. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Azole use should be avoided during pregnancy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doses of the azoles are chosen depending upon the severity of the infection being treated and the formulation being used. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Infectious Diseases Society of America guidelines recommend monitoring serum levels in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      for the treatment of aspergillosis, histoplasmosis, or blastomycosis. Although assays are available for each of the triazoles, there are no uniform guidelines for monitoring serum concentrations of the other agents. However, it has become standard of care at many centers to perform therapeutic drug monitoring of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      to assure efficacy in the treatment of serious fungal infections and, in the case of voriconazole, to avoid toxicity. Serum concentrations of voriconazole and posaconazole should be checked in all patients receiving treatment doses of these agents. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Serum drug concentration monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The azoles are involved in many important drug-drug interactions, the most important of which involve oxidative drug metabolism via the cytochrome P450 enzyme system. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/1\">",
"      Gallagher JC, Dodds Ashley ES, Drew RH, Perfect JR. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother 2003; 4:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/2\">",
"      Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008; 29:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/3\">",
"      Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/4\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/5\">",
"      Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/6\">",
"      Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol 2007; 2:37.",
"     </a>",
"    </li>",
"    <li>",
"     Diflucan&reg; Package Insert. Roerig, a Division of Pfizer, Inc. New York, NY 2008. file://media.pfizer.com/files/products/uspi_diflucan.pdf (Accessed on December 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/8\">",
"      Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/9\">",
"      Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988; 157:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/10\">",
"      Foulds G, Brennan DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988; 28:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/11\">",
"      Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987; 31:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/12\">",
"      Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997; 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/13\">",
"      Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/14\">",
"      Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/15\">",
"      Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997; 37:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/16\">",
"      Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/17\">",
"      Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/18\">",
"      Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993; 7:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/19\">",
"      Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/20\">",
"      Nivoix Y, Lev&ecirc;que D, Herbrecht R, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/21\">",
"      Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/22\">",
"      Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/23\">",
"      Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis. Clin Exp Dermatol 1991; 16:374.",
"     </a>",
"    </li>",
"    <li>",
"     Sporanox Package Insert. Janssen Pharmaceuticals. Titusville, NJ 2008. file://www.ortho-mcneil.com/ortho-mcneil/shared/pi/sporanox.pdf (Accessed on December 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/25\">",
"      Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother 2000; 45:371.",
"     </a>",
"    </li>",
"    <li>",
"     VFEND (voriconazole) highlights of prescribing information. file://labeling.pfizer.com/ShowLabeling.aspx?id=618 (Accessed on May 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/27\">",
"      Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 2004; 64:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/28\">",
"      Neofytos D, Lombardi LR, Shields RK, et al. Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis 2012; 54:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/29\">",
"      Weiler S, Fiegl D, MacFarland R, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/30\">",
"      Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011; 12:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/31\">",
"      Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother 2012; 56:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/32\">",
"      Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 2003; 23:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/33\">",
"      Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/34\">",
"      Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/35\">",
"      Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57:218.",
"     </a>",
"    </li>",
"    <li>",
"     Noxafil (posaconazole). Prescribing information. Kenilworth, NJ: Schering, NJ, 2006. file://www.fda.gov/medwatch/SAFETY/2008/May_PI/Noxafil_PI.pdf (Accessed on December 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/37\">",
"      Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/38\">",
"      Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48:3543.",
"     </a>",
"    </li>",
"    <li>",
"     Ketoconazole product information. Apotex Corp, Toronto, Ontario, Canada, 2004. file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3287 (Accessed on December 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/40\">",
"      Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/41\">",
"      Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/42\">",
"      Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/43\">",
"      Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991; 35:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/44\">",
"      Carver PL, Berardi RR, Knapp MJ, et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother 1994; 38:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/45\">",
"      Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997; 41:2714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/46\">",
"      Pappas PG, Kauffman CA, Perfect J, et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995; 123:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/47\">",
"      Sharkey PK, Rinaldi MG, Dunn JF, et al. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991; 35:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/48\">",
"      Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001; 357:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/49\">",
"      Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/50\">",
"      Boussaud V, Daudet N, Billaud EM, et al. Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus. J Heart Lung Transplant 2008; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/51\">",
"      Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/52\">",
"      Miller DD, Cowen EW, Nguyen JC, et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/53\">",
"      Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/54\">",
"      Ibrahim SF, Singer JP, Arron ST. Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole. Dermatol Surg 2010; 36:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/55\">",
"      Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/56\">",
"      Wang TF, Wang T, Altman R, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 2009; 9:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/57\">",
"      Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011; 52:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/58\">",
"      Gerber B, Guggenberger R, Fasler D, et al. Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood 2012; 120:2390.",
"     </a>",
"    </li>",
"    <li>",
"     VFEND (voriconazole) tablets, IV for infusion and oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) &ndash; November 2011. file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm283035.htm (Accessed on January 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/60\">",
"      Philips JA, Marty FM, Stone RM, et al. Torsades de pointes associated with voriconazole use. Transpl Infect Dis 2007; 9:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/61\">",
"      Alkan Y, Haefeli WE, Burhenne J, et al. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 2004; 39:e49.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Antiviral Drugs Advisory Committee. Briefing document for voriconazole",
"(oral and intravenous formulations). file://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_pfizer.pdf (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/63\">",
"      Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci 2010; 99:3291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/64\">",
"      Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/65\">",
"      Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 1992; 11:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/66\">",
"      Sanchez JM, Moya G. Fluconazole teratogenicity. Prenat Diagn 1998; 18:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/67\">",
"      Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005; 73:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/68\">",
"      Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997; 72:253.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants. file://www.fda.gov/Drugs/DrugSafety/ucm266030.htm (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/70\">",
"      Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999; 19:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/71\">",
"      N&oslash;rgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother 2008; 62:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/72\">",
"      Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996; 175:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/73\">",
"      Sorensen HT, Nielsen GL, Olesen C, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999; 48:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/74\">",
"      Bar-Oz B, Moretti ME, Bishai R, et al. Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. Am J Obstet Gynecol 2000; 183:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/75\">",
"      Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/76\">",
"      Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 55:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/77\">",
"      Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 2011; 55:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/78\">",
"      Koselke E, Kraft S, Smith J, Nagel J. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother 2012; 67:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/79\">",
"      Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/80\">",
"      Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/81\">",
"      Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/82\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/83\">",
"      Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/84\">",
"      Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/85\">",
"      Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/86\">",
"      Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/87\">",
"      Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/88\">",
"      Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/89\">",
"      Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/90\">",
"      Hostetler JS, Heykants J, Clemons KV, et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993; 37:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/91\">",
"      Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/92\">",
"      Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/93\">",
"      Trifilio SM, Yarnold PR, Scheetz MH, et al. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009; 53:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/94\">",
"      Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/95\">",
"      Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/96\">",
"      Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008; 61:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/97\">",
"      Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Drug Evaluation and Research. Posaconazole (Noxafil, Schering-Plough)-Clinical Pharmacology and Biopharmaceutics Reviews. Application 22-003, 22 December 2005. file://www.fda.gov/cder/foi/nda/2006/022003s000_Noxafil_ClinPharmR.pdf (Accessed on January 30, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/99\">",
"      Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 2011; 55:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/100\">",
"      Vaes M, Hites M, Cotton F, et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother 2012; 56:6298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/101\">",
"      Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/102\">",
"      Albengres E, Le Lou&euml;t H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/103\">",
"      Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/104\">",
"      Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994; 18:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/105\">",
"      Nicolau DP, Crowe HM, Nightingale CH, Quintiliani R. Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother 1995; 29:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/106\">",
"      Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 2004; 43:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/107\">",
"      Geist MJ, Egerer G, Burhenne J, et al. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother 2007; 51:3455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/108\">",
"      Spina E, Arena D, Scordo MG, et al. Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. Ther Drug Monit 1997; 19:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/109\">",
"      Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009; 51:437.",
"     </a>",
"    </li>",
"    <li>",
"     Krishna, G, Moton, A, Ma, L, et al. Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008. Available at: file://www.blackwellpublishing.com/eccmid18/abstract.asp?id=69164 (Accessed July 17, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/111\">",
"      Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis 2009; 48:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/112\">",
"      Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56:5503.",
"     </a>",
"    </li>",
"    <li>",
"     Noxafil (posaconazole) oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) &ndash; September 2010 and June 2012. file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm228417.htm (Accessed on January 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/114\">",
"      Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/115\">",
"      Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008; 28:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/4/36938/abstract/116\">",
"      Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:552.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 495 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-190.81.197.98-24A80F9498-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36938=[""].join("\n");
var outline_f36_4_36938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGIC ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ketoconazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drug-specific adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ketoconazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ketoconazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SERUM DRUG CONCENTRATION MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Overview of CYP and other effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Major drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Selected clinical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/51/9021\" title=\"table 2\">",
"      Significant interactions involving triazoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/6/3181\" title=\"table 3\">",
"      Major interactions involving triazoles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=related_link\">",
"      Candida infections of the bladder and kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17271?source=related_link\">",
"      Coccidioidal meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21848?source=related_link\">",
"      Coccidioidomycosis in compromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/4/29765?source=related_link\">",
"      Fluconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/17/34069?source=related_link\">",
"      Itraconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/52/38720?source=related_link\">",
"      Ketoconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26807?source=related_link\">",
"      Manifestations and treatment of extrapulmonary coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=related_link\">",
"      Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/18/35112?source=related_link\">",
"      Posaconazole: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29912?source=related_link\">",
"      Treatment of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15210?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/60/12234?source=related_link\">",
"      Voriconazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_4_36939="Echo asymptomatic murmurs";
var content_f36_4_36939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Echocardiography in asymptomatic patients with cardiac murmurs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that echocardiography is useful in asymptomatic patients with the following cardiac murmurs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Diastolic murmurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Continuous murmurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Late systolic murmurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Murmurs associated with ejection clicks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Murmurs that radiate to the neck or back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Grade 3 or louder midpeaking systolic murmurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of usefulness of echocardiography in asymptomatic patients with the following cardiac murmurs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Murmurs associated with other abnormal physical findings on cardiac examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Murmurs associated with an abnormal electrocardiogram or chest x-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that echocardiography is not useful in asymptomatic patients with the following murmurs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Grade 2 or softer midsystolic murmurs considered innocent or functional by an experienced observer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36939=[""].join("\n");
var outline_f36_4_36939=null;
var title_f36_4_36940="Side effects of antitrypanosomal drugs";
var content_f36_4_36940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated percentage of patients (all age groups) that experience adverse effects of benznidazole and nifurtimox",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approximate percentage (range) of patients with adverse effect*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        Nifurtimox",
"       </td>",
"       <td>",
"        Anorexia and weight loss",
"       </td>",
"       <td>",
"        50 (17-70)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyneuropathy&bull;",
"       </td>",
"       <td>",
"        25 (15-36)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea/vomiting",
"       </td>",
"       <td>",
"        15 (5-33)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal discomfort",
"       </td>",
"       <td>",
"        15 (9-25)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"       <td>",
"        15 (13-19)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dizziness/vertigo",
"       </td>",
"       <td>",
"        15 (9-25)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insomnia",
"       </td>",
"       <td>",
"        12 (10-19)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nervous excitation, mood changes",
"       </td>",
"       <td>",
"        15 (9-27)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myalgia",
"       </td>",
"       <td>",
"        12 (11-14)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disorientation",
"       </td>",
"       <td>",
"        7 (6-10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paresthesia",
"       </td>",
"       <td>",
"        3 (2-3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukopenia",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        Benznidazole",
"       </td>",
"       <td>",
"        Allergic dermatitis&Delta;",
"       </td>",
"       <td>",
"        30 (14-50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy&bull;",
"       </td>",
"       <td>",
"        30 (0-43)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia and weight loss",
"       </td>",
"       <td>",
"        15 (6-24)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insomnia",
"       </td>",
"       <td>",
"        5 (0-6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and/or vomiting",
"       </td>",
"       <td>",
"        4 (2-6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukopenia&loz;",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia&loz;",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysgeusia&sect;",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on reported frequences from retrospective case series and clinical trials in which standard drug doses were given.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Dose-dependent, usually occurs late in course. Reversible but may take months.",
"      <br>",
"       &Delta; Not dose dependent. Discontinue drug if severe. Stevens Johnson syndrome reported.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Requires discontinuation.",
"        <br>",
"         &sect; Reversible but may take weeks.",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36940=[""].join("\n");
var outline_f36_4_36940=null;
var title_f36_4_36941="Neurohormonal stimulat HF";
var content_f36_4_36941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Functional and structural modifications following neurohormonal stimulation in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36941=[""].join("\n");
var outline_f36_4_36941=null;
var title_f36_4_36942="Insertion of anvil of circular stapler into ileum";
var content_f36_4_36942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion of anvil of circular stapler into ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anvil is secured to the ileum with a purse string suture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36942=[""].join("\n");
var outline_f36_4_36942=null;
var title_f36_4_36943="SNAQ";
var content_f36_4_36943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Simplified nutritional appetite questionnaire (SNAQ)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 568px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wilson, MG, Thomas, PR, Rubenstein, LZ, et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr 2005; 82:1074. Copyright &copy; 2005 American Society for Nutrition.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_4_36943=[""].join("\n");
var outline_f36_4_36943=null;
